### CONFERENCE CALL OF THE SURGERY ENDORSEMENT MAINTENANCE 2010 STEERING COMMITTEE

### November 29, 2011

*Committee Members Present*: Arden Morris, MD, MPH, FACS (Co-chair), University of Michigan; Curtis Collins, PharmD, MS, BCPS AQ-ID, University of Michigan Health System; Peter Dillon, MD, MSc, Penn State Hershey Medical Center; Richard Dutton, MD, MBA, Anesthesia Quality Institute; Vivienne Halpern, MD, FACS, Carl T Hayden VA Medical Center; Terry Rogers, MD, The Foundation for Health Care Quality; Connie Steed, MSN, RN, CIC, Greenville Hospital System; Carol Wilhoit, MD, MS, Blue Cross Blue Shield of Illinois.

*NQF Staff Present*: Heidi Bossley, MSN, MBA, Vice President of Performance Measures; Alexis Forman Morgan, MPH, Senior Project Manager; Karen Pace, PhD, RN, Senior Director; Jessica Weber, Project Analyst, MPH.

*Measure Developers Present:* Dale Bratzler, Oklahoma Foundation of Medical Quality; Carla Chronister, Oklahoma Foundation for Medical Quality; Jeffrey Geppert, Battelle Memorial Institute; Bob Jasak, American College of Surgeons; Wanda Johnson, Oklahoma Foundation for Medical Quality; Tim Kresowik, Society of Vascular Surgeons; Karen Nakano, Centers for Medicare & Medicaid Services; Mamatha Pancholi, Agency for Healthcare Research and Quality; Patrick Romano, University of California-Davis; David Shahian, The Society of Thoracic Surgeons; Jill Shelly, American College of Surgeons; Cynthia Shewan, The Society of Thoracic Surgeons.

Others Present: Elvira Ryan, The Joint Commission; Joann Sorra, Westat; Carla Zema, Zema Consulting.

The audio recording from the meeting can be found here.

### **MEETING PROCESS**

Mrs. Forman Morgan welcomed the Steering Committee and provided a brief overview of the agenda. The purpose of this call was to:

- continue reviewing the remaining Phase II measures;
- determine if any of the AAA measures are related or competing;
- review harmonization plans for multiple prophylactic antibiotic measures; and
- review measure 1741: Patient experience with surgical care based on the consumer assessment of healthcare providers and systems (CAHPS)<sup>TM</sup> surgical care survey.

The measure developers/stewards were available on the call to respond to questions from the Committee as needed.

### **MEASURE EVALUATION SUMMARY**

The following summary includes the Committee's original evaluation of the measures and any follow-up since the May 4-5 in-person meeting.

### **Measures and Evaluations**

The summary below displays follow-up of 9 measures, including actions taken by the Steering Committee on conditional recommendations or preliminary review. (See the <u>summary</u> from the May 4-5 meeting for the original evaluation of the measures.)

Information related to the measures that were discussed on this call is highlighted.

| <b>LEGEND:</b> Y=Yes; N = No; A = Abstain; C = Completely; P = Partially; M = Minimally; N = Not at all | LEGEND: Y= Yes; 1 | I = No; A = Abstain; C = 0 | Completely; $P = Partially; M =$ | = Minimally; $N = Not$ at all |
|---|-------------------|----------------------------|----------------------------------|-------------------------------|
|---|-------------------|----------------------------|----------------------------------|-------------------------------|

### Cardiac, Appendectomy and Pancreatic Resection

| 0365 Pancreatic resection mortality rate (IQI 9) (risk adjusted) | 2 |
|--|---|
| 0366 Pancreatic resection volume (IQI 2)                         | 4 |

### **Cardiac and Vascular**

| 0357 Abdominal aortic aneurysm (AAA) repair volume (IQI 4)                        | 6 |
|---|---|
| 0359 Abdominal aortic artery (AAA) repair mortality rate (IQI 11) (risk adjusted) |   |
| 1523 In-hospital mortality following elective open repair of small AAAs           |   |
| 1534 In-hospital mortality following elective EVAR of small AAAs                  |   |
|   |   |

### General, Ophthalmology, Orthopedics and Pediatrics

| 1741 Patient experience with surgical care based on the consumer assessment of healthcare providers and |   |
|---|---|
| systems (CAHPS) ® surgical care survey  | ł |

### General, Prophylaxis and Wound Dehiscence

| 0128 Duration of antibiotic prophylaxis for cardiac surgery patients 1            | 6 |
|---|---|
| 0529 Prophylactic antibiotics discontinued within 24 hours after surgery end time | 7 |

0365 Pancreatic resection mortality rate (IQI 9) (risk adjusted)

**Description:** Percentage of adult hospital discharges with procedure code of pancreatic resection with an in-hospital death, stratified by benign and malignant disease.

**Numerator Statement:** Number of deaths (DISP=20) among cases meeting the inclusion and exclusion rules for the denominator. **Denominator Statement:** Hospital discharges, age 18 years and older, with ICD-9-CM pancreatic resection code procedure and a diagnosis code of pancreatic cancer in any field, stratified by benign and malignant disease.

Exclusions: Exclude cases:

• missing discharge disposition (DISP=missing), gender (SEX=missing), age (AGE=missing), quarter (DQTR=missing), year

(YEAR=missing) or principal diagnosis (DX1 =missing)

transferring to another short-term hospital (DISP=2)

• MDC 14 (pregnancy, childbirth, and puerperium)

ICD-9-CM codes:

577.0

#### 0365 Pancreatic resection mortality rate (IQI 9) (risk adjusted)

#### Acute pancreatitis

Adjustment/Stratification: Risk adjustment method widely or commercially available The predicted value for each case is computed using a hierarchical model (logistic regression with hospital random effect) and covariates for gender, age in years (in 5-year age groups), All Patient Refined-Diagnosis Related Group (APR-DRG) and APR-DRG risk-of-mortality subclass. The reference population used in the model is the universe of discharges for states that participate in the HCUP State Inpatient Databases (SID) for the year 2007 (updated annually), a database consisting of 43 states and approximately 30 million adult discharges. The expected rate is computed as the sum of the predicted value for each case divided by the number of cases for the unit of analysis of interest (i.e., hospital, state, and region). The risk adjusted rate is computed using indirect standardization as the observed rate divided by the expected rate, multiplied by the reference population rate/User has the optin to stratify by gender, age (5-year age groups), race/ ethnicity, primary payer, and custom stratifiers./ Malignant Disease: ICD-9-CM pancreatic cancer diagnosis codes: 1520 MALIGNANT NEOPL DUODENUM 1561 MAL NEO EXTRAHEPAT DUCTS 1562 MAL NEO AMPULLA OF VATER 1570 MAL NEO PANCREAS HEAD 1571 MAL NEO PANCREAS BODY 1572 MAL NEO PANCREAS TAIL 1573 MAL NEO PANCREATIC DUCT 1574 MAL NEO ISLET LANGERHANS 1578 MALIG NEO PANCREAS NEC 1579 MALIG NEO PANCREAS NOS Benign Disease: All other cases Level of Analysis: Facility/ Agency Type of Measure: Outcome Data Source: Electronic administrative data/ claims Measure Steward: Agency for Healthcare Research and Quality | 540 Gaither Road | Rockville | Maryland | 20850 Steering Committee Recommendation for Endorsement: Pending final recommendation. Rationale: The measure is based on strong evidence and evaluation criteria are met. With stratification that includes benign and malignant disease and both endovascular and open repair, its usefulness is enhanced. If applicable, Conditions/Questions for Developer: Overarching comment: Please provide feasibility of reporting mortality stratified by institutional volume (e.g., high, medium, low volume with parameters for each) rather than having rate and mortality separated. De.2 Ensure measure description accurately captures measure focus. 1. 2a.8 Denominator Details: Do not limit to pancreatic resection for cancer - could stratify by malignant and benign. Also, 2. consider providing volume as well as rate. 2a.9 Denominator Exclusions: Please remove 'transferring to another short-term hospital (DISP=2)' from the exclusions. 3. 4. 2a.9 Denominator Exclusions: Add exclusion for pancreatitis. Measures 0365 and 0366 should be fully harmonized in order to properly report as a pair. This will involve including all pancreatic disease in both the numerator and denominator of both measures. They can then be stratified by malignant and benign disease. Note: Discussion of Related and Competing measures may result in additional requests to developers specific to harmonization. **Developer Response:** 

- 1. AHRQ agrees to revise the measure description to more accurately capture the measure focus
- 2. AHRQ agrees to harmonize the mortality and volume indicator denominators to include benign disease in the mortality measure. Note that the mortality and volume indicator (0366) are designated as paired measures
- 3. This request is problematic for a few reasons. First, the outcome of interest (in-hospital mortality) is not observed for these

| 0365 Pancreatic resection mortality rate (IQI 9) (risk adjusted)   |
|--|
| cases. Second, it is possible that a single case may be counted twice (once for the transferring hospital, once for the receiving hospital). Third, removing this exclusion would require using data that linked patients across hospitalizations (in order to avoid the issues #1 and #2), which is not readily available for individual hospitals across institutions. Therefore, we respectively defer a definitive response to this request pending the routine availability of linked hospitalization data, or at a minimum additional analysis using such data of the potential impact of removing the exclusion.  |
| 4. AHRQ agrees to add an exclusion for pancreatitis  |
| Steering Committee Follow-up:  |
| <ol> <li>The Steering Committee expressed their concern about transferred patients being excluded from the measure. AHRQ responded that the number is less that 1 percent and the majority is transfer of convenience for the patient. The Steering Committee agreed that the response from the developer was adequate.</li> <li>This was one of three related measures considered for potential harmonization. The three included: maintenance measure 0365: Pancreatic resection mortality rate (IQI 9); maintenance measure 0366: Pancreatic resection volume (IQI 2); and endorsed measure 0738: Survival predictor for pancreatic resection surgery. Discussion of the three measures is included here. The Steering Committee requested the measure developer continue its expedited work to combine measures 0365 and 0366, including benign disease. After some discussion, the Members agreed that because measures 0365 and 0366 are risk adjusted and measure 0738 is not, that recommendations related to harmonization of numerator and denominator should not be advanced at this time.</li> </ol> |
| On the September 13 conference call, the Steering Committee reviewed Measures 0365 and 0366 which have been harmonized to reflect both benign and malignant disease. The developer stated that empirical literature has predominately focused on resections for cancer and there is a substantial difference in short term outcomes between high volume and low volume centers. They noted the potential value of including benign disease as a separate stratum. The developer also indicated that they continue to work on combining the measures into a single measure. Progress to this end will be reviewed on a subsequent conference call.  |
| On the November 29 call, the developer indicated that testing results were provided for the revised measures (0365 and 0366) that are now stratified by benign and malignant disease. The Committee was satisfied with the testing results and recommended both measures for endorsement. The Committee will vote on final recommendation for endorsement of this measure following the conference call.   |
| 1. Importance to Measure and Report:   |
| (1a. Impact; 1b. Performance gap; 1c. Outcome or Evidence)<br>Rationale: The evidence supports the measure's focus on pancreatic resections for cancer and while it is a low-volume procedure,   |
| mortality rates are high and merit tracking.   |
| <b>2. Scientific Acceptability of Measure Properties:</b><br>(2a. Precise specifications; 2b. Reliability testing; 2c. Validity testing; 2d. Exclusions justified; 2e. Risk adjustment/stratification; 2f. Meaningful differences; 2g. Comparability; 2h. Disparities)   |
| <b>Rationale:</b> The measure was considered scientifically acceptable. The Committee discussed the importance of separate measures focusing on a pancreatic resection for cancer and a pancreatic resection for benign disease and determined that both could be captured in a single measure that is stratified to report each.  |
| 3. Usability:<br>(3a. Meaningful/useful for public reporting and quality improvement; 3b. Harmonized; 3c. Distinctive or additive value to existing measures)  |
| Rationale: This measure is in use in multiple states and healthcare systems and is reported on HCUPnet as well as used in the MONAHRQ system that is provided for public reporting and quality improvement.  |
| <b>4. Feasibility:</b><br>(4a. Clinical data generated during care process; 4b. Electronic sources; 4c. Exclusions – no additional data source; 4d. Susceptibility to inaccuracies/ unintended consequences identified 4e. Data collection strategy can be implemented)  |
| Rationale: This measure was considered feasible; data is obtained from electronic claims and chart abstraction.  |
|  |
| 0366 Pancreatic resection volume (IQI 2)<br>Description: Number of adult hospital discharges with procedure for pancreatic resection, stratified by benign and malignant disease.  |
| Numerator Statement: Hospital discharges, age 18 years and older, with ICD-9-CM codes for pancreatic resection procedure, stratified by benign and malignant disease.<br>Denominator Statement: Not applicable   |
|  |
| Exclusions: Not applicable<br>Adjustment/Stratification: No risk adjustment necessary/.  |

Adjustment/Stratification: No risk adjustment necessary/. Malignant Disease: ICD-9-CM pancreatic cancer diagnosis codes:

| 0366 Pancreatic resection volume (IQI 2)   |
|--|
| 1520<br>MALICNIANT NEODI DUODENIUM   |
| MALIGNANT NEOPL DUODENUM   |
| 1561<br>MAL NEO EXTRAHEPAT DUCTS   |
| 1562   |
| MAL NEO AMPULLA OF VATER   |
| 1570   |
| MAL NEO PANCREAS HEAD  |
| 1571   |
| MAL NEO PANCREAS BODY  |
| 1572   |
| MAL NEO PANCREAS TAIL  |
| 1573   |
| MAL NEO PANCREATIC DUCT  |
| 1574   |
| MAL NEO ISLET LANGERHANS   |
| 1578   |
| MALIG NEO PANCREAS NEC   |
| 1579   |
| MALIG NEO PANCREAS NOS   |
| Benign Disease:  |
| All other cases  |
| Level of Analysis: Facility/ Agency  |
| Type of Measure: Structure/management  |
| Data Source: Electronic administrative data/ claims  |
| Measure Steward: Agency for Healthcare Research and Quality   540 Gaither Road   Rockville   Maryland   20850<br>Steering Committee Recommendation for Endorsement: Pending final recommendation.                          |
| <b>Rationale:</b> The measure was considered important and cited strong evidence. With reporting as a pair with 0365 and stratification that   |
| includes benign and malignant disease and both endovascular and open repair, its usefulness is enhanced.   |
| If applicable, Conditions/Questions for Developer:   |
| 1. De.2 Ensure measure description accurately captures measure focus.  |
| <ol> <li>2. 2a.3 Numerator Details: Partial resections and partial operations should be included in 0366,</li> </ol>   |
| 3. <u>2a.8 Denominator Details</u> : Do not limit to pancreatic resection for cancer.  |
| 4. 2a.9 Denominator Exclusions: Please remove 'transferring to another short-term hospital (DISP=2)' from the exclusions.  |
| 5. 2a.9 Denominator Exclusions: Add exclusion for pancreatitis.  |
| 6. 2b.3 and 2.c.3 Testing Results: Text speaks to esophageal resection. Please provide correct information and advise if there   |
| are other such errors within the submission that have required correction.   |
| Measures 0365 and 0366 should be fully harmonized in order to properly report as a pair. This will involve including all pancreatic  |
| disease in both the numerator and denominator of both measures. They can then be stratified by malignant and benign disease.   |
| Note: Discussion of Related and Competing measures may result in additional requests to developers specific to harmonization.  |
| Developer Response:  |
| 1. AHRQ agrees to revise the measure description to more accurately capture the measure focus  |
| 2. AHRQ agrees to include partial resections and partial operations  |
| 3. The volume measure contains no such exclusion. However, in general AHRQ agrees to harmonize the mortality and volume  |
| indicator denominators to include benign disease in the mortality measure. Note that the mortality (0365) and volume indicator   |
| are designated as paired measures.   |
| <ol> <li>The volume measure contains no such exclusion; however, see note above regarding harmonization</li> <li>The volume measure contains no such exclusion; however, see note above regarding harmonization</li> </ol> |
| <ol> <li>Such erroneous references shall be corrected</li> </ol>   |
| Steering Committee Follow-up:  |
| 1. The Steering Committee agreed that the response from the developer was adequate.  |
| 2. This was one of three related measures considered for potential harmonization. The three included: maintenance measure  |
| 0365: Pancreatic resection mortality rate (IQI 9); maintenance measure 0366: Pancreatic resection volume (IQI 2); and  |
| endorsed measure 0738: Survival predictor for pancreatic resection surgery. Discussion of the three measures is included   |
| here. The Steering Committee requested the measure developer continue its expedited work to combine measures 0365 and  |
| 0366, including benign disease. After some discussion, the Members agreed that because measures 0365 and 0366 are risk   |
|  |

#### 0366 Pancreatic resection volume (IQI 2)

adjusted and measure 0738 is not, that recommendations related to harmonization of numerator and denominator should not be advanced at this time.

On the September 13 conference call, the Steering Committee reviewed Measures 0365 and 0366 which have been harmonized to reflect both benign and malignant disease. The developer stated that empirical literature has predominately focused on resections for cancer and there is a substantial difference in short term outcomes between high volume and low volume centers. They noted the potential value of including benign disease as a separate stratum. The developer also indicated that they continue to work on combining the measures into a single measure. Progress to this end will be reviewed on a subsequent conference call.

On the November 29 call, the developer indicated that testing results were provided for the revised measures (0365 and 0366) that are now stratified by benign and malignant disease. The Committee was satisfied with the testing results and recommended both measures for endorsement. The Committee will vote on final recommendation for endorsement of this measure following the conference call.

#### 1. Importance to Measure and Report:

(1a. Impact; 1b. Performance gap; 1c. Outcome or Evidence)

Rationale: The evidence supports the measure's focus on pancreatic resections for cancer and while it is a low-volume procedure, the impact in terms of mortality is important to track and report.

#### 2. Scientific Acceptability of Measure Properties:

(2a. Precise specifications; 2b. Reliability testing; 2c. Validity testing; 2d. Exclusions justified; 2e. Risk adjustment/stratification; 2f. Meaningful differences; 2g. Comparability; 2h. Disparities)

**Rationale:** The measure was considered scientifically acceptable. The Committee discussed the importance of separate measures focusing on a pancreatic resection for cancer and a pancreatic resection for benign disease and determined that both could be captured in a single measure to be stratified to report each.

3. Usability:

(3a. Meaningful/useful for public reporting and quality improvement; 3b. Harmonized; 3c. Distinctive or additive value to existing measures)

**Rationale:** This measure is in use in multiple states and healthcare systems and is reported on HCUPnet as well as used in the MONAHRQ system that is provided for public reporting and quality improvement.

4. Feasibility:

(4a. Clinical data generated during care process; 4b. Electronic sources; 4c. Exclusions – no additional data source; 4d. Susceptibility to inaccuracies/ unintended consequences identified 4e. Data collection strategy can be implemented)

Rationale: This measure was considered feasible; data is obtained from electronic claims and chart abstraction.

#### 0357 Abdominal aortic aneurysm (AAA) repair volume (IQI 4)

Description: Count of adult hospital discharges in a one year time period with a procedure code of AAA repair. Numerator Statement: Discharges, age 18 years and older, with an abdominal aortic aneurysm (AAA) repair procedure and a primary or secondary diagnosis of AAA. Denominator Statement: Not applicable. Exclusions: Not applicable. Adjustment/Stratification: no risk adjustment necessary/ The stratification of the denominator for open vs. endovascular and ruptured vs. unruptured involve the following codes in the denominator specification: AAA Repair ( ICD-9-CM Procedure Codes: OPEN : '3834' = '1' /\* AORTA RESECTION & ANAST \* '3844' = '1' /\* RESECT ABDM AORTA W REPL \*/ '3864' = '1' /\* EXCISION OF AORTA \*/ /\* ENDOVASCULAR \*/: '3971' = '1' /\* ENDO IMPL GRFT ABD AORTA \*/ /\* Include Only: AAA \*/ /\* ICD-9-CM Diagnosis Codes: \*/ /\* RUPTURED \*/; '4413 ' = '1' /\* RUPT ABD AORTIC ANEURYSM \*/ /\* UNRUPTURED \*/: '4414 ' = '1' /\* ABDOM AORTIC ANEURYSM \*/ Level of Analysis: Facility/ Agency Type of Measure: Structure/management

#### 0357 Abdominal aortic aneurysm (AAA) repair volume (IQI 4)

Data Source: Electronic administrative data/ claims

- Measure Steward: Agency for Healthcare Research and Quality | 540 Gaither Road | Rockville | Maryland | 20850
- Steering Committee Recommendation for Endorsement: Conditional <u>No did not pass Importance to Measure and Report Y-10; N-</u> 11. Pending final recommendation.

**Rationale:** The measure initially did not pass the importance criterion; however, the Committee asked for additional information. With that information, the Committee reconsidered the measure. Final action is pending receipt and consideration of a measure that combines 0357 and 0359.

#### If applicable, Conditions/Questions for Developer:

- 1. Overarching Comment: The Steering Committee vote regarding the NQF evaluation criterion of "Importance" was split with 10 voting yes and 11 voting no and a number of members noted the measure should only be reported with the related mortality measure. The developer will want to review the measure in its entirety in this light and provide whatever additional information/specification including value as a paired measure with mortality that it believes appropriate. Should specifications change, it is important to provide information regarding testing with the changes.
- 2. <u>2a. 11 Stratification Details/Variables</u>: Measure should stratify the measure by endovascular and open repairs.

Note: Discussion of Related and Competing measures may result in additional requests to developers specific to harmonization. As discussed the developer should meet with SVS to harmonize or blend measures concerning AAA

#### **Developer Response:**

- 1. AHRQ agrees to stratify the measure by endovascular and open repairs, but notes that additional methodological development will be required to ensure the measures have adequate reliability.
- 2. AHRQ noted at the meeting that the volume and mortality measures are to be reported as paired measures though some users may not have the information to report both.

### Steering Committee Follow-Up:

The Steering Committee was concerned about volume being reported as a singular measure.

- 1. The Steering Committee requested information regarding needed methodological changes for the measure based on the endovascular and open repair stratification and will further consider the measure with that information. AHRQ will also further clarify the risk adjustment model.
- 2. The Steering Committee was concerned that the developer had not addressed creating a composite of the volume (0357) and morbidity measure (0359). Members noted that the developer had agreed to stratify the measure by endovascular and open repairs but that the measure did have reliability testing for the requested change. The Steering Committee asked for additional information about how the developer would redevelop their risk stratification model. On the August 3 conference call, the developer discussed the measure together with Measure 0359 and highlighted preliminary results of revising the measure with four strata. The developer is continuing to explore how the outcomes information can be put back together with volume for the requested composite/combined measures. The measure will move forward as a composite rather than as two measures.

On the September 13 conference call, the Steering Committee reviewed the developer's revisions to reflect four strata, ruptured or unruptured aneurysms repaired by open or endovascular approaches. These four components will be reported separately within this measure in addition to reporting overall measure performance. The developer also responded to questions about testing results and public reporting details to the satisfaction of the Committee.

On the November 29 call, the developer stated that measure 0359: Abdominal aortic artery (AAA) repair mortality rate (IQI 11) was revised and is now adjusted by volume. Although volume has been incorporated into measure 0359, the developer stated that measure 0357: Abdominal aortic aneurysm (AAA) repair volume (IQI 4) should remain. Some Committee members voiced their concerns as to whether volume should be a stand-alone measure. Members of the Committee also indicated that both measures are used by a variety of individuals for a variety of reasons. It was noted on the call that measures 0357 and 0359 are to be reported as paired measures. During the related and competing measures discussion, the Committee agreed that measures 0357 and 0359 were competing against the Leapfrog measure, measure 0736: Survival predictor for abdominal aortic aneurysm (AAA). The Committee determined that the AHRQ measures (0357 and 0359) were superior to measure 0736 as measures 0357 and 0359 distinguish between open vs. endovascular procedures and the measures are risk adjusted. The Committee will vote on each criteria and final recommendation for endorsement of this measure following the conference call.

#### 1. Importance to Measure and Report: Y-10; N-11

(1a. Impact; 1b. Performance gap; 1c. Outcome or Evidence)

**Rationale:** The measure would provide key information to the public about AAA mortality, but does not provide separate information on EVARs and open repairs. The vote is reflective of the debate related to the value and implications of separately reporting open and endovascular repairs. AHRQ representatives indicated that the stratification is a component of the current software; however, the Committee would like to see this specifically reflected in the specifications of the measure. AHRQ representatives indicated that a separate risk adjustment model could be developed for open and endovascular procedures with both ruptured and unruptured

#### 0357 Abdominal aortic aneurysm (AAA) repair volume (IQI 4)

aneurysms. The majority of AAA repairs are done endovascularly and open repairs have become more complicated.

#### 2. Scientific Acceptability of Measure Properties:

(2a. Precise specifications; 2b. Reliability testing; 2c. Validity testing; 2d. Exclusions justified; 2e. Risk adjustment/stratification; 2f. Meaningful differences; 2g. Comparability; 2h. Disparities)

#### Rationale: 3. Usability:

(3a. Meaningful/useful for public reporting and quality improvement; 3b. Harmonized; 3c. Distinctive or additive value to existing measures)

#### Rationale:

#### 4. Feasibility:

(4a. Clinical data generated during care process; 4b. Electronic sources; 4c. Exclusions – no additional data source; 4d. Susceptibility to inaccuracies/ unintended consequences identified 4e. Data collection strategy can be implemented) Rationale:

#### 0359 Abdominal aortic artery (AAA) repair mortality rate (IQI 11) (risk adjusted)

**Description:** Percent of adult hosptial discharges in a one-year time period with a procedure code of AAA repair and a diagnosis of AAA with an in-hospital death.

**Numerator Statement:** Number of deaths (DISP=20) among cases meeting the inclusion and exclusion rules for the denominator. **Denominator Statement:** Discharges, age 18 years and older, with ICD-9-CM AAA repair code procedure and a diagnosis of AAA in any field. The denominator may be stratified by open vs. endovascular procedures, and ruptured vs. un-ruptured AAA. **Exclusions:** Exclude cases:

• missing discharge disposition (DISP=missing), gender (SEX=missing), age (AGE=missing), quarter (DQTR=missing), year

(YEAR=missing) or principal diagnosis (DX1 =missing)

• transferring to another short-term hospital (DISP=2)

• MDC 14 (pregnancy, childbirth, and puerperium)

Adjustment/Stratification: risk adjustment method widely or commercially available The predicted value for each case is computed using a hierarchical model (logistic regression with hospital random effect) and covariates for gender, age in years (in 5-year age groups), All Patient Refined-Diagnosis Related Group (APR-DRG) and APR-DRG risk-of-mortality subclass. The reference population used in the model is the universe of discharges for states that participate in the HCUP State Inpatient Databases (SID) for the year 2007 (updated annually), a database consisting of 43 states and approximately 30 million adult discharges. The expected rate is computed as the sum of the predicted value for each case divided by the number of cases for the unit of analysis of interest (i.e., hospital, state, and region). The risk adjusted rate is computed using indirect standardization as the observed rate divided by the expected rate, multiplied by the reference population rate.

Risk adjustment factors: sex

age 18-24; age 25-29; age 30-34; age 35-39; age 40-44; age 45-49; age 50-54; age 55-59; age 60-64; age 65-69; age 70-74; age 75-79; age 80-84; age 85+

ADRG 1731 (other vascular procedures-minor)

ADRG 1732 (other vascular procedures-moderate)

ADRG 1733 (other vascular procedures-major)

ADRG 1734 (other vascular procedures-extreme)

ADRG 1691 (major thoracic and abdominal vascular procedures-minor)

ADRG 1692 (major thoracic and abdominal vascular procedures-moderate)

ADRG 1693 (major thoracic and abdominal vascular procedures-major)

ADRG 1694 (major thoracic and abdominal vascular procedures-extreme

MDC 5 (Cardiovascular)

Transfer-in status

Gender, age (5-year age groups), race/ ethnicity, primary payer, custom

The stratification of the denominator for open vs. endovascular and ruptured vs. unruptured involves the following codes in the denominator specification:

AAA Repair

ICD-9-CM Procedure Codes:

OPEN '3834' = '1' /\* AORTA RESECTION & ANAST \*/

'3844' = '1' /\* RESECT ABDM AORTA W REPL \*/

'3864' = '1' /\* EXCISION OF AORTA \*/

**ENDOVASCULAR** 

#### 0359 Abdominal aortic artery (AAA) repair mortality rate (IQI 11) (risk adjusted)

'3971' = '1' /\* ENDO IMPL GRFT ABD AORTA \*/

AAA

ICD-9-CM Diagnosis Codes:

RUPTURED

'4413 ' = '1' /\* RUPT ABD AORTIC ANEURYSM \*/ UNRUPTURED

'4414 ' = '1' /\* ABDOM AORTIC ANEURYSM \*/

Level of Analysis: Facility/ Agency

Type of Measure: Outcome

Data Source: Electronic administrative data/ claims

Measure Steward: Agency for Healthcare Research and Quality | 540 Gaither Road | Rockville | Maryland | 20850

Steering Committee Recommendation for Endorsement: Pending final recommendation.

**Rationale:** The measure initially did not pass the importance criterion; however, the Steering Committee engaged in extensive discussion of the volume and mortality measures as noted in review of 0357 above. The Committee asked for additional information and with that information, reconsidered the measure. Final action is pending receipt and consideration of a measure that combines 0357 and 0359.

#### If applicable, Conditions/Questions for Developer:

- 1. <u>2a.11 Stratification Details/Variables</u>: a) Stratify the measure by endovascular and open repairs as well as emergency vs. elective repair; b) specify the risk stratification model used; 3) identify settings where the model has been validated in addition to the training data set in which it was developed or provide other supporting data as to its validity.
- 2. <u>2b.3 Testing Results</u>: Please provide information about signal to noise ratio.

Note: Discussion of Related and Competing measures may result in additional requests to developers specific to harmonization. As discussed, the developer should meet with SVS to harmonize or blend measures concerning AAA. **Developer Response:** 

- a) As noted above, AHRQ agrees to stratify the measure by endovascular and open repairs; in addition, AHRQ agrees to stratify by ruptured vs. un-ruptured aneurysm (which is what we assume you mean by emergency vs. elective repair); but AHRQ again notes that additional methodological development will be required to ensure the measures have adequate reliability; b) the risk stratification model is specified below; c) the model has been validated on the State Inpatient Databases (SID), which consists of hospital discharge data from 40 states (constituting about 90% of hospital discharges in the U.S) for the years 2001-2008
- 2. The signal to noise ratio is the ratio of the between hospital variance (signal) to the within hospital variance (noise). The formula is signal / (signal + noise). The ratio itself is only a diagnostic for the degree of variance in the risk-adjusted rate systematically associated with the provider. Therefore, what matters is the magnitude of the variance in the "smoothed" rate (that is, the variance in the risk-adjusted rate after the application of the univariate shrinkage estimator based on the signal ratio). What the data demonstrate is systematic variation in the provider level rate of 2.6 to 7.6 per 100 from the 5<sup>th</sup> to 95<sup>th</sup> percentile <u>after</u> a signal ratio of 0.307 is applied as the shrinkage estimator (that is, after accounting for variation due to random factors).

| Parameter | Label            | DF | Estimate | Standard Error | Wald Chi-Square | Pr > Chi-Square |
|-----------|------------------|----|----------|----------------|-----------------|-----------------|
| Intercept |                  | 1  | -6.6044  | 0.1713         | 1486.04         | 0.0000          |
| Sex       | Female           | 1  | 0.4539   | 0.0747         | 36.95           | 0.0000          |
| Age       | 65 to 74         | 1  | 0.4879   | 0.1072         | 20.72           | 0.0000          |
| Age       | 75 to 79         | 1  | 0.8737   | 0.1201         | 52.97           | 0.0000          |
| Age       | 80 to 84         | 1  | 1.1092   | 0.1200         | 85.50           | 0.0000          |
| Age       | 85+              | 1  | 1.4440   | 0.1359         | 112.97          | 0.0000          |
| APR-DRG   | '1691' to '1692' | 1  | 1.6789   | 0.1623         | 107.05          | 0.0000          |
| APR-DRG   | '1693' to '1694' | 1  | 3.9127   | 0.1523         | 659.72          | 0.0000          |
| APR-DRG   | '1733' to '1734' | 1  | 3.1568   | 0.1676         | 354.55          | 0.0000          |
| MDC       | 5                | 1  | 2.6400   | 0.1483         | 316.85          | 0.0000          |
| MDC       | Other            | 1  | 2.9536   | 0.2252         | 172.05          | 0.0000          |
| RUPTURED  |                  | 1  | 2.0565   | 0.0808         | 647.42          | 0.0000          |

#### able 3. Risk Adjustment Coefficients for IQI #11— AAA Repair Mortality

#### 0359 Abdominal aortic artery (AAA) repair mortality rate (IQI 11) (risk adjusted)

Note: The APR-DRG consists of the DRG and the risk-of-mortality subclass (minor (1), moderate (2), major (3) and extreme (4)). **Steering Committee Follow-Up:** 

- 1. The Steering Committee requested information regarding needed methodological changes for the measure based on the endovascular and open repair stratification and will further review the measure with that information. AHRQ will also further clarify the risk adjustment model.
- 2. The Steering Committee was concerned that the developer had not addressed creating a composite of the volume (0357) and morbidity measure (0359). It noted that the developer had agreed to stratify the measure by endovascular and open repairs but that the measure did not have any reliability testing for the requested change. The Steering Committee asked for additional information about how the developer would redevelop their risk stratification model. On the August 3 conference call, the developer highlighted preliminary results about the measure's stratification. A Steering Committee member questioned whether the measure was useful for endovascular un-ruptured repairs, if the difference between the best performing hospitals was 0.00 percent and worst performing hospitals was 0.75 percent repairs, which was considered minimal. Additionally, it was noted that open ruptured repairs also showed little difference between the best performing hospitals at 24.74 percent and the worst performing hospitals at 26.53 percent. The Steering Committee resolved that while some of the collected data may show small differences, the measure would also show areas of variation. The developer further explained that they could use the data to identify hospitals that performed at better or worse than average but for other subsets.

On the August 3 conference call, the developer highlighted preliminary results of revising the measure with four strata – ruptured vs. unruptured; and open vs. endovascular repair using available data from a period of years using data from 1700 hospitals, of which 500 do endovascular repair of ruptured aneurysms. Based on the preliminary data of that stratification, a number of issues were discussed including whether the measure was useful for endovascular un-ruptured repairs, given minimal differences between the best performing hospitals (0.00 percent) and worst performing hospitals (0.75 percent); small differences in open ruptured repairs between hospitals that performed better than expected (24.74 percent) and those that performed worse than expected (26.53 percent); risk stratification approaches using inpatient diagnoses vs. clinical data or outpatient diagnoses. The Steering Committee opined that while some of the collected data may show small differences, the breakdown can show areas of variation that warrant measurement and follow up. The developer is continuing to explore how the outcomes information can be put back together with volume for the requested composite/combined measures.

On the September 13 conference call, the Steering Committee reviewed the developer's revisions to reflect four strata, ruptured or unruptured aneurysms repaired by open or endovascular approaches. These four components will be reported separately within this measure in addition to reporting overall measure performance. The developer also responded to questions about testing results and public reporting details to the satisfaction of the Committee.

On the November 29 call, the developer stated that measure 0359: Abdominal aortic artery (AAA) repair mortality rate (IQI 11) was revised and is now adjusted by volume. Although volume has been incorporated into measure 0359, the developer stated that measure 0357: Abdominal aortic aneurysm (AAA) repair volume (IQI 4) should remain. Some Committee members voiced their concerns as to whether volume should be a stand-alone measure. Members of the Committee also indicated that both measures are used by a variety of individuals for a variety of reasons. It was noted on the call that measures 0357 and 0359 are to be reported as paired measures. During the related and competing measures discussion, the Committee agreed that measures 0357 and 0359 were competing against the Leapfrog measure, measure 0736: Survival predictor for abdominal aortic aneurysm (AAA). The Committee determined that the AHRQ measures (0357 and 0359) were superior to measure 0736 as measures 0357 and 0359 distinguished between open vs. endovascular procedures and the measures are risk adjusted. The Committee will vote on each criteria and final recommendation for endorsement of this measure following the conference call.

1. Importance to Measure and Report: Y-10; N-11

(1a. Impact; 1b. Performance gap; 1c. Outcome or Evidence)

**Rationale:** The measure would provide key information to the public about AAA volume, but does not provide separate information on EVARs and open repairs. The majority of AAA repairs are done endovascularly and open repairs have become more complicated.

#### 2. Scientific Acceptability of Measure Properties:

(2a. Precise specifications; 2b. Reliability testing; 2c. Validity testing; 2d. Exclusions justified; 2e. Risk adjustment/stratification; 2f. Meaningful differences; 2g. Comparability; 2h. Disparities)

### Rationale:

3. Usability:

(3a. Meaningful/useful for public reporting and quality improvement; 3b. Harmonized; 3c. Distinctive or additive value to existing measures)

#### Rationale:

#### 0359 Abdominal aortic artery (AAA) repair mortality rate (IQI 11) (risk adjusted)

#### 4. Feasibility:

(4a. Clinical data generated during care process; 4b. Electronic sources; 4c. Exclusions – no additional data source; 4d. Susceptibility to inaccuracies/ unintended consequences identified 4e. Data collection strategy can be implemented) Rationale:

#### 1523 In-hospital mortality following elective open repair of small AAAs

**Description:** Percentage of aymptomatic patients undergoing open repair of small abdominal aortic aneurysms (AAA)who die while in hospital. This measure is proposed for both hospitals and individual providers.

**Numerator Statement:** Mortality following elective open repair of asymptomatic AAAs in men with < 6 cm dia and women with < 5.5 cm dia AAAs

**Denominator Statement:** All elective open repairs of asymptomatic AAAs in men with < 6 cm dia and women with < 5.5 cm dia AAAs **Exclusions:** > 6 cm minor diameter - men

> 5.5 cm minor diameter - women

Symptomatic AAAs that required urgent/emergent (non-elective) repair

Adjustment/Stratification: No risk adjustment necessary/No stratification is required for this measure.

Level of Analysis: Can be measured at all levels, Clinicians : Group, Clinicians : Individual, Facility/ Agency

Type of Measure: Outcome

Data Source: Registry data

Measure Steward: Society for Vascular Surgery | 633 N. St. Clair, 24th floor | Chicago | Illinois | 60611

Steering Committee Recommendation for Endorsement: Conditional Y-9; N-11; A-1

Rationale: The evidence supports the measure's focus on small AAAs repairs and it provides important outcome data; however the Committee had a number of questions for which it requested developer response before further consideration of the measure.

#### If applicable, Conditions/Questions for Developer:

Overall comment: Based on the narrow margin of the Steering Committee vote related to having met criteria for endorsement the measure will be reconsidered with the response to the questions and conditions below.

- 1. <u>De2. Brief Description and 2a.1 Numerator Statement</u>: Suggested addition of 30-day mortality with in-hospital mortality. Also, please clarify whether aneurysm size can be collected using administrative (i.e., is widely available outside the Northern New England registry), or available clinical data and the added burden of such collection.
- 2. <u>2a. Measure Specifications</u>: Provide a timeframe for availability of newly created CPT2 codes to make this a universally applicable measure.
- 3. <u>2a.3 Numerator Details</u>: Reword the numerator details here and throughout where registry is specified to be clear that a specific registry (i.e., SVS, VSGNE) is not required to collect the data.
- 4. <u>2b Reliability Testing and 2c Validity Testing</u>: Advise what testing will be needed and completed for the suggested modification to 30 day mortality?
- 5. <u>2d. Exclusions</u>: Provide reconcile sample size and data for what is being measured. Also reconcile aneurysm size in the population of interest and the sizes specified throughout.
- 6. <u>2h. Disparities in Care</u>: Provide information about disparities or plans to be able to provide data.
- 7. <u>3a.2 Use in a Public Reporting Initiative</u>: Please provide plans for public reporting (within 3 years).

Note: Discussion of Related and Competing measures may result in additional requests to developers specific to harmonization **Developer Response:** 

- 1. We suggest in-hospital instead of 30-day mortality for several reasons. We have previously studied mortality within the first year after open AAA repair. In-hospital mortality was 2.1% and 30-day mortality was 2.3% in VSGNE, since almost every patient who died within 30 days was never discharged. [Predicting 1-year mortality after elective abdominal aortic aneurysm repair. Beck et al, J Vasc Surg. 2009.49:838-44]. Further, in-hospital mortality is more easily obtained and audited, and is immediately available at the time of discharge. Finally, there is lower cost for obtaining in-hospital mortality a more appropriate measure and have not changed this portion of the application. AAA size is readily available in the medical record, and is tracked not only in VSGNE, but the SVS VQI registry, which now comprises more than 80 centers in 30 states across the U. S., and is expected to comprise all states by 2012. The SVS VQI is the de facto national registry for vascular surgery. While AAA size cannot currently be collected using administrative data, we expect that the great majority of vascular surgeons in the U.S. will be participating in SVS VQI by 2012.
- It is our plan to request CPT2 codes to allow coding of AAA diameter by claims data. These codes will be reviewed by the CPT Performance Measures Advisory Group's next meeting, which is scheduled for July 18-19, 2011. The CPT Editorial Panel will then have to approve the codes before they can appear in any CPT publication. The Editorial Panel will meet October 13-15, 2011.

#### 1523 In-hospital mortality following elective open repair of small AAAs

- 3. Numerator and denominator have been edited to clearly state than ANY registry tracking the appropriate variables can be used for reporting all of the current measures being proposed by SVS.
- 4. As stated above, we have already compared in-hospital and 30-day mortality in 748 patients undergoing open elective AAA repair in VSGNE and found no advantage to using 30-day mortality, which is more difficult and more expensive to collect.
- 5. This section has been expanded. Data are provided for large and small AAAs, showing difference in operative mortality, emphasizing the reason for including only SMALL dia AAAs in this measure. Patients with larger diameter AAAs cannot be included without complex risk adjusting that is not available. However, data indicate that MANY small AAAs are being electively repaired, and it is in this population that a quality measure is needed. Most patients with much larger AAAs always warrant treatment, since the AAA rupture risk is so high if not treated.
- 6. Disparities have not been reported. As additional data are acquired from the SVS registry across a much larger and varied population, future disparities may be discovered.
- SVS intends to request that all of these measures be included in PQRS, and expects CMS to begin publishing PQRS data in the near future. Independent of this, SVS plans to request permission from participating providers and hospitals to publish these measures on the SVS public website.

#### **Steering Committee Follow-up:**

The Steering Committee expressed concern about the documentation and tracking of aneurysm size outside of the SVS registry though it was believed that this could be captured based on chart notes. The Steering Committee will have a follow-up call to review this measure as part of the AAA Repair related and competing measures once a composite has been created for measures 0357 and 0359.

On the November 29 call, during the related and competing measures discussion, the Committee determined that measures 1523 and 1534 were not competing against measures 0357, 0359 and 0736 because measures' 1523 and 1534 focus is different. The SVS measures focus on the successful outcomes of the procedure for those performed on smaller AAAs, which should only be performed if the patients are low risk and if treatment is really warranted. SVS, the developer, did indicate that they are currently expanding the data source of these two measures, measures 1523 and 1534, to include claims data. The Committee agreed to recommend measures 1523 and 1534 for endorsement as they currently stand with the expectation that the measure developer will harmonize with the AHRQ measures (0357 and 0359) if and when they revise measures 1523 and 1534 to include claims data. The Committee will vote on final recommendation for endorsement of this measure following the conference call.

#### 1. Importance to Measure and Report: Y-18; N-3; A-0

(1a. Impact; 1b. Performance gap; 1c. Outcome or Evidence)

**Rationale:** The measure provides important outcome data. More AAA repairs are being conducted; although, they may not be medically necessary. However, the data provided in the measure included both small and large aneurysms, despite the stated measure's focus on only small AAAs. High mortality levels may encourage a process review.

#### 2. Scientific Acceptability of Measure Properties: C-2; P-16; M-2; A-1

(2a. Precise specifications; 2b. Reliability testing; 2c. Validity testing; 2d. Exclusions justified; 2e. Risk adjustment/stratification; 2f. Meaningful differences; 2g. Comparability; 2h. Disparities)

**Rationale:** The Committee described the importance of extending the measure to 30-day mortality to identify adverse outcomes. The Committee stated the numerator time window, while verbally explained satisfactorily, could be confusing to users. Testing was questioned; while the measure focused on small aneurysms, testing was conducted on large aneurysms.

#### 3. Usability: C-4; P-11; M-4; A-2

(3a. Meaningful/useful for public reporting and quality improvement; 3b. Harmonized; 3c. Distinctive or additive value to existing measures)

Rationale: The data used for the measure is drawn from registry data that includes both claims and chart abstracted data thus is usable for registry participants although for non-registry participants, the data would prove challenging to collect.

#### 4. Feasibility: C-4; P-10; M-3; A-4

(4a. Clinical data generated during care process; 4b. Electronic sources; 4c. Exclusions – no additional data source; 4d. Susceptibility to inaccuracies/ unintended consequences identified 4e. Data collection strategy can be implemented)

**Rationale:** The registry group from which data for this measure is drawn is about 10 hospitals thus information about feasibility is limited both in terms of the number of facilities in which tested and testing with only registry data. At present there is no mechanism for identifying small aneurysms with administrative data. The developer is working to develop CPT II codes that would allow aneurysm size to be captured and reported with administrative data. This would require new/additional specifications for the measure. It was noted that the measure could be revised and limited to mortality unrelated to aneurysm size that could be collected using administrative data; this would require further modification of the measure.

#### 1534 In-hospital mortality following elective EVAR of small AAAs

**Description:** Percentage of patients undergoing elective endovascular repair of small asymptomatic abdominal aortic aneurysms (AAA) who die while in hospital. This measure is proposed for both hospitals and individual providers.

|          | nospital mortality following elective EVAR of small AAAs  |
|----------|---|
|          | <b>or Statement:</b> Mortality following elective endovascular AAA repair of asymptomatic AAAs in men with < 6 cm dia and women 5 cm dia AAAs |
| Denomir  | nator Statement: All elective endovascular repairs of asymptomatic AAAs in men with < 6 cm dia and women with < 5.5 cm dia                    |
| AAAs     |   |
| Exclusio |   |
|          | / that includes hospitalization details, AAA diameter and discharge status is required to identify patients for denominator                   |
|          | . The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI) and the Vascular Study Group of New England                          |
|          | ) registries records such information. Patients who underwent endovascular AAA repair are included if their aneurysm was                      |
|          | matic and small (< 6cm dia in men, <5.5 cm dia in women, judged by preoperative imaging).   |
|          | ent/Stratification: No risk adjustment necessary/No stratification is required for this measure.  |
|          | Analysis: Can be measured at all levels, Clinicians : Group, Clinicians : Individual, Facility/ Agency  |
|          | Measure: Outcome  |
|          | urce: Registry data   |
|          | Steward: Society for Vascular Surgery   633 N. St. Clair, 22nd Floor   Chicago   Illinois, 60611  |
|          | Committee Recommendation for Endorsement: Conditional <u>Y-9; N-12; A-0</u>   |
|          | e: The evidence supports the measure's focus on small AAAs repairs and it provides important outcome data; however, the                       |
|          | ee has a number of questions for which it requested developer response before further consideration of the measure.                           |
|          | able, Conditions/Questions for Developer:   |
|          | the narrow margin of the Steering Committee vote related to having met criteria for endorsement, the committee will                           |
|          | er the measure with the response to the questions and conditions below.   |
| 1.       | De2. Brief Description and 2a.1 Numerator Statement: Suggested modification- addition of 30-day mortality with in-hospital                    |
|          | mortality. Also, please clarify whether aneurysm size can be collected using administrative (i.e., is widely available outside the            |
| •        | Northern New England registry), or available clinical data and the added burden of such collection.   |
| 2.       | <u>2a Measure Specifications</u> : Scope of the measure as specified will have limited impact. Please reevaluate.                             |
| 3.       | 2b Reliability Testing and 2c Validity Testing: Identify the testing that will need to be completed for the suggested                         |
|          | modifications?  |
| 4.       | <u>2d. Exclusions</u> : Provide reconcile sample size and data for what is being measured. Also reconcile aneurysm size in the                |
| _        | population of interest and the sizes specified throughout.  |
| 5.       | <u>2h</u> . Disparities in Care: Providing information about disparities or plans to be able to provide same.                                 |
| 6.       | <u>3a</u> .2 Use in a public reporting initiative: Please provide plans for public reporting (within 3 years).                                |
|          | er Response:  |
| 1.       | We suggest in-hospital instead of 30-day mortality for several reasons. We have previously studied mortality within the first                 |
|          | year after elective endovascular AAA repair. In-hospital mortality was 0.48% and 30-day mortality was 0.50% in VSGNE,                         |
|          | since almost every patient who died within 30 days was never discharged. [Predicting 1-year mortality after elective abdominal                |
|          | aortic aneurysm repair. Beck et al, J Vasc Surg. 2009.49:838-44]. Further, in-hospital mortality is more easily obtained and                  |
|          | audited, and is immediately available at the time of discharge. Finally, there is lower cost for obtaining in-hospital results, since         |
|          | subsequent patient contact after discharge is not necessary. We believe that these advantages make in-hospital mortality a                    |
|          | more appropriate measure and have not changed this portion of the application. AAA size is readily available in the medical                   |
|          | record, and is tracked not only in VSGNE, but the SVS VQI registry, which now comprises more than 80 centers in 30 states                     |
|          | across the U. S., and is expected to comprise all states by 2012. The SVS VQI is the de facto national registry for vascular                  |
|          | surgery. While AAA size cannot currently be collected using administrative data, we expect that the great majority of vascular                |
| 0        | surgeons in the U.S. will be participating in SVS VQI by 2012.  |
| 2.       | We are not certain as to the exact specification within 2a to which this comment is applied. However, we disagree that this                   |
|          | measure will have limited impact. Most AAAs are small when detected, and there is a general suspicion that too many small                     |
|          | AAAs are being repaired unnecessarily, with a resulting unnecessary operative mortality. This measure will focus attention on                 |
|          | the elective mortality rate of endovascular AAA repair in these patients. Although the median mortality rate is low in VSGNE,                 |
|          | there is significant variation among hospitals, and large clinical trials have documented this mortality to be 2-3%, even for small           |
|          | AAAs. If 10,000 patients per year in the US undergo unnecessary endovascular repair of such small AAAs, a 3% mortality                        |
|          | results in 300 avoidable deaths. This is an important quality measure, and needs to be established in parallel with our open                  |
|          | AAA repair measure, so that surgeons performing AAA repair can/must report their outcomes independent of which technique                      |
|          | they use. We have not changed the measure form, because it was not clear where to insert this information.                                    |
| 3.       | As stated above, we have already compared in-hospital and 30-day mortality in 639 patients undergoing elective endovascular                   |
|          | AAA repair in VSGNE and found no advantage to using 30-day mortality, which is more difficult and more expensive to collect.                  |
| 4.       | This section has been expanded. Data are provided for large and small AAAs, showing difference in operative mortality,                        |
|          | emphasizing the reason for including only SMALL dia AAAs in this measure. Patients with larger diameter AAAs cannot be                        |
|          | included without complex risk adjusting that is not available. However, data indicate that MANY small AAAs are being                          |

#### 1534 In-hospital mortality following elective EVAR of small AAAs

electively repaired, and it is in this population that a quality measure is needed. Most patients with much larger AAAs always warrant treatment, since the AAA rupture risk is so high if not treated.

- 5. Disparities have not been reported. As additional data are acquired from the SVS registry across a much larger and varied population, future disparities may be discovered.
- SVS intends to request that all of these measures be included in PQRS, and expects CMS to begin publishing PQRS data in the near future. Independent of this, SVS plans to request permission from participating providers and hospitals to publish these measures on the SVS public website.

#### **Steering Committee Follow-up:**

The Steering Committee expressed concern about the documentation and tracking of aneurysm size outside of the SVS registry. The Steering Committee will have a follow-up call to review this measure as part of the AAA Repair related and competing measures once a composite has been created for measures 0357 and 0359.

On the November 29 call, during the related and competing measures discussion, the Committee decided that measures 1523 and 1534 were not competing against measures 0357, 0359 and 0736 because measures' 1523 and 1534 focus is different. The SVS measures focus on the successful outcomes of the procedure for those performed on smaller AAAs, which should only be performed if the patients are low risk and if treatment is really warranted. SVS, the developer, did indicate that they are currently revising the data source of these two measures, measures 1523 and 1534, to include claims data. The Committee agreed to recommend measures 1523 and 1534 for endorsement as they currently stand with the expectation that the measure developer will harmonize with the AHRQ measures (0357 and 0359) if and when they revise measures 1523 and 1534 to include claims data. The Committee will vote on final recommendation for endorsement of this measure following the conference call.

### 1. Importance to Measure and Report: Y-21; N-0 ; A-0

(1a. Impact; 1b. Performance gap; 1c. Outcome or Evidence)

**Rationale:** The measure provides important outcome data. More AAA repairs are being conducted; although, they may not be medically necessary. However, the data provided in the measure included both small and large aneurysms, despite the measure's focus on only small AAAs. High mortality levels may encourage a process review.

2. Scientific Acceptability of Measure Properties: C-5; P-13; M-3; N-0

(2a. Precise specifications; 2b. Reliability testing; 2c. Validity testing; 2d. Exclusions justified; 2e. Risk adjustment/stratification; 2f. Meaningful differences; 2g. Comparability; 2h. Disparities)

**Rationale:** The Committee discussed the importance of extending the measure to 30-day mortality to identify adverse outcomes. The Committee stated that the time window may be confusing.

#### 3. Usability: C-3; P-15; M-2; N-1

(3a. Meaningful/useful for public reporting and quality improvement; 3b. Harmonized; 3c. Distinctive or additive value to existing measures)

Rationale: In the future the measure could be adjusted to be applicable for other procedures.

4. Feasibility: C-5; P-10; M-5; N-1

(4a. Clinical data generated during care process; 4b. Electronic sources; 4c. Exclusions – no additional data source; 4d. Susceptibility to inaccuracies/ unintended consequences identified 4e. Data collection strategy can be implemented)

**Rationale:** The measure did not provide wide spread testing data and may not be feasible without the registry. The developer is attempting to create CPT II codes to facilitate use beyond the registry in the future.

#### 1741 Patient experience with surgical care based on the consumer assessment of healthcare providers and systems (CAHPS) ® surgical care survey

**Description:** The following 6 composites and 1 single-item measure are generated from the Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Surgical Care Survey. Each measure is used to assess a particular domain of surgical care quality from the patient's perspective.

Measure 1: Information to help you prepare for surgery (2 items)

Measure 2: How well surgeon communicates with patients before surgery (4 items)

Measure 3: Surgeon's attentiveness on day of surgery (2 items)

NQF Review #: 1741

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable 2

Measure 4: Information to help you recover from surgery (4 items)

Measure 5: How well surgeon communicates with patients after surgery (4 items)

Measure 6: Helpful, courteous, and respectful staff at surgeon's office (2 items)

Measure 7: Rating of surgeon (1 item)

The Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Surgical Care Survey

is administered to adult patients (age 18 and over) having had a major surgery as defined by CPT

| 1741 Patient experience with surgical care based on the consumer assessment of healthcare providers and systems (CAHPS)<br>® surgical care survey                                       |
|---|
| codes (90 day globals) within 3 to 6 months prior to the start of the survey.   |
| Numerator Statement: The calculation of CAHPS survey composites uses a proportional scoring method, which basically generates a   |
| proportion for each response option. (For more detail see Attachment H, Reporting Measures for the CAHPS Surgical Care Survey)  |
|   |
| The numerator is the average proportion of respondents who answered each response category  |
| across the questions in the composite.  |
| For example for measures, 1, 2, 4, 5, 6 scoring would involve the following steps:  |
| Step 1 – Calculate the proportion of cases in each response category for the each question:   |
| P1 = Proportion of respondents who answered "yes, definitely"   |
| 2 = Proportion of respondents who answered "yes, somewhat"  |
| P3 = Proportion of respondents who answered "no"  |
| Calculate all proportions for each of the questions in the composite.   |
| Step 2 – Combine responses from the questions to form the composite   |
| Calculate the average proportion responding to each category across the questions in the composite. For example for measure 2, in th  |
| How Well Surgeon Communicates With Patients Before  |
| Surgery" (four items), the calculations would be as follows:  |
| PC1 = Composite proportion who said "yes, definitely" = (P11 + P21 + P31 + P41) / 4   |
| PC2 = Composite proportion who said "yes, somewhat" = (P12 + P22 + P32 + P42) / 4   |
| PC3 = Composite proportion who said "no" = (P13 + P23 + P33 + P43) / 4  |
| The numerators for the top box or proportionate scoring method of measures 1, 2, 4, 5, and 6 is PC1   |
| or the average proportion of respondents who answered "Yes, definitely" across the items within   |
| each composite.   |
| The numerator for measure 3 is the average proportion of respondents who answered "Yes" across  |
| he items in this composite.   |
| The numerator for the global item is the proportion of respondents who answered 9-10 to this item.  |
| See also Attachment H: Reporting Measures for the CAHPS Surgical Care Survey.   |
| <b>Denominator Statement:</b> The major criteria for selecting patients were having had a <b>major</b> surgery as defined by CPT codes (90 day  |
| globals) within 3 to 6 months prior to the start of the survey. [For the full list of CPT codes, see Attachment J]. Results will typically be   |
| compiled over a 12-month period.  |
| Exclusions: For each composite, respondents who answer at least one item of the composite are included in the denominator. The  |
| following patients would be excluded from all composites:   |
| • Surgical patients whose procedure was greater than 6 months or less than 3 months prior to the start of the survey.   |
| • Surgical patients younger than 18 years old.  |
| • Surgical patients younger than no years old.  |
|   |
| <ul> <li>Surgery performed had to be scheduled and not an emergency procedure since emergency procedures are unlikely to have visits with<br/>the surgery before the surgery</li> </ul> |
| the surgeon before the surgery.   |
| • Multiple surgery patients within the same household can be included in the sampling frame. However, once one patient in the   |
| nousehold is sampled, any other patients in the same household would be excluded from being sampled in order to minimize survey   |
| purden to the household.  |
| All data present for all respondents are that are not excluded are used.  |
| Adjustment/Stratification: Case-mix adjustment/No stratification is required for this measure.  |
| Level of Analysis: Clinicians: Individual, Group  |
| Type of Measure: Composite  |
| Data Source: Survey-patient   |
| Measure Steward: American College of Surgeons   20 F Street NW, Suite 1000   Washington   District of Columbia, 20001   |
| Steering Committee Recommendation for Endorsement: The Steering Committee will vote on this measure after receiving addition  |
| requested information from the developer.   |
| Rationale:  |
| f applicable, Conditions/Questions for Developer:   |
| 1. Provide final data results on the scale  |
| 2. Revise the composite submission form to: a) make it easier to understand what is being submitted for review; and b) provide  |
|   |
| the requested information in the correct section of the submission form.  |
|   |
| Developer Response:   |
| 1. Importance to Measure and Report:  |

**1. Importance to Measure and Report:** (1a. Impact; 1b. Performance gap; 1c. Outcome or Evidence)

#### 1741 Patient experience with surgical care based on the consumer assessment of healthcare providers and systems (CAHPS) ® surgical care survey

#### Rationale:

#### 2. Scientific Acceptability of Measure Properties:

(2a. Precise specifications; 2b. Reliability testing; 2c. Validity testing; 2d. Exclusions justified; 2e. Risk adjustment/stratification; 2f. Meaningful differences; 2g. Comparability; 2h. Disparities)

### Rationale:

3. Usability:

(3a. Meaningful/useful for public reporting and quality improvement; 3b. Harmonized; 3c. Distinctive or additive value to existing measures)

#### Rationale:

#### 4. Feasibility:

(4a. Clinical data generated during care process; 4b. Electronic sources; 4c. Exclusions – no additional data source; 4d. Susceptibility to inaccuracies/ unintended consequences identified 4e. Data collection strategy can be implemented) Rationale:

#### 0128 Duration of antibiotic prophylaxis for cardiac surgery patients

**Description:** Percent of patients aged 18 years and older undergoing cardiac surgery whose prophylactic antibiotics were discontinued within 48 hours after surgery end time

**Numerator Statement:** Number of patients undergoing cardiac surgery whose prophylactic antibiotics were discontinued within 48 hours after surgery end time

Denominator Statement: Number of patients undergoing cardiac surgery

Exclusions: Exclusions:

-Patients who had a principal diagnosis suggestive of preoperative infectious diseases

-Patients whose ICD-9-CM principal procedure was performed entirely by Laparoscope

-Patients enrolled in clinical trials

-Patients with documented infection prior to surgical procedure of interest

-Patients who expired perioperatively

-Patients who were receiving antibiotics more than 24 hours prior to surgery

-Patients who were receiving antibiotics within 24 hours prior to arrival

-Patients who did not receive any antibiotics during this hospitalization

-Patients with reasons to extend antibiotics

This list will be provided in the STS Adult Cardiac Surgery Database Data Manager's Training Manual as acceptable exclusions.

Adjustment/Stratification: no risk adjustment necessary/No stratification is required for this measure.

Level of Analysis: Clinicians: Group, Facility/ Agency, Population: Counties or cities, Population: National, Population: Regional/ network, Population: States

Type of Measure: Process

Data Source: Registry data

Massure Stoward: Society of Thorasia Su

Measure Steward: Society of Thoracic Surgeons | 633 North Saint Clair Street, Suite 2320 | Chicago | Illinois | 60611

**Steering Committee Recommendation for Endorsement: Conditional** <u>Y-17, N-2; A-0</u> Pending final recommendation. **Rationale:** The measure was considered important due to the potential for prolonged antibiotic use and the percent of antimicrobial resistance.

#### **Steering Committee Follow-up:**

This was one of four related measures considered for potential harmonization. The four included: maintenance measure 0529: Prophylactic antibiotics discontinued within 24 hours after surgery end time; endorsed measure 0637: Discontinuation of prophylactic antibiotics (cardiac procedures); maintenance measure 0128: Duration of antibiotic prophylaxis for cardiac surgery patients; and endorsed measure 0271: Discontinuation of prophylactics antibiotics (non-cardiac procedures). Discussion of the four measures is included here. The Steering Committee determined there were no competing measures in the group. Members requested that the developers evaluate the extent to which harmonization of the four measures could be accomplished. They asked that initial focus be on refining the exclusions to ensure they capture the same information and that end times of 24 and 48 hours be examined in terms of whether there are cardiac surgeries for which the different end times are specifically indicated and if so that they be specified for capture within the relevant measures. Also, members asked that the laparoscopy exclusion be removed from Measure 0128. For those measures not within the current project (AMA-PCPI measures 0637 and 0271), NQF staff will relay the requests of the Committee for their action as they update and test the measures.

The measure developers provided a response to the Committee's request. The developers are currently working to schedule a

#### 0128 Duration of antibiotic prophylaxis for cardiac surgery patients

conference call to begin discussing harmonization and/or combining the antibiotic prophylaxis measures per the Committee's request. On the November 29 call, the Committee agreed to recommend measure 0128 as it currently stands with the expectation that the harmonized measure will be submitted to the next Surgery project in 2013. The Committee will vote on final recommendation for endorsement of this measure following the conference call.

#### 1. Importance to Measure and Report: Y-18, N-1

(1a. Impact; 1b. Performance gap; 1c. Outcome or Evidence)

Rationale: The measure noted a performance gap in appropriate antibiotic administration, which can increase the incidence of deep sternal wound infection or antimicrobial resistance.

2. Scientific Acceptability of Measure Properties: C-10; P-6; M-2; N-1

(2a. Precise specifications; 2b. Reliability testing; 2c. Validity testing; 2d. Exclusions justified; 2e. Risk adjustment/stratification; 2f. Meaningful differences; 2g. Comparability; 2h. Disparities)

Rationale: The Committee debated the time period for antibiotic discontinuation reviewing the merits of 48 hours versus 24 hours.

**3. Usability:** <u>C-13; P-6; M-0; N-0</u>

(3a. Meaningful/useful for public reporting and quality improvement; 3b. Harmonized; 3c. Distinctive or additive value to existing measures)

Rationale: The measure will be reported as part of a composite in the future.

4. Feasibility: C-11; P-8; M-0; N-0

(4a. Clinical data generated during care process; 4b. Electronic sources; 4c. Exclusions – no additional data source; 4d. Susceptibility to inaccuracies/ unintended consequences identified 4e. Data collection strategy can be implemented) **Rationale:** The measure presented minimal evidence of costs.

#### 0529 Prophylactic antibiotics discontinued within 24 hours after surgery end time

**Description:** Surgical patients whose prophylactic antibiotics were discontinued within 24 hours after Anesthesia End Time (48 hours for CABG or Other Cardiac Surgery). The Society of Thoracic Surgeons (STS) Practice Guideline for Antibiotic Prophylaxis in Cardiac Surgery (2006) indicates that there is no reason to extend antibiotics beyond 48 hours for cardiac surgery and very explicitly states that antibiotics should not be extended beyond 48 hours even with tubes and drains in place for cardiac surgery.

**Numerator Statement:** Number of surgical patients whose prophylactic antibiotics were discontinued within 24 hours after Anesthesia End Time (48 hours for CABG or Other Cardiac Surgery).

Denominator Statement: All selected surgical patients with no evidence of prior infection. Included Populations:

An ICD-9-CM Principal Procedure Code of selected surgeries (as defined in Appendix A, Table 5.10 for ICD-9-CM codes) AND

An ICD-9-CM Principal Procedure Code of selected surgeries (as defined in Appendix A, Table 5.01-5.08 for ICD-9-CM codes) **Exclusions:** Excluded Populations:

Patients less than 18 years of age

Patients who have a length of Stay greater than 120 days

Patients who had a principal diagnosis suggestive of preoperative infectious diseases (as defined in Appendix A, Table 5.09 for ICD-9-CM codes)

Patients whose ICD-9-CM principal procedure was performed entirely by Laparoscope

Patients enrolled in clinical trials

Patients whose ICD-9-CM principal procedure occurred prior to the date of admission

Patients with physician/advanced practice nurse/physician assistant (physician/APN/PA) documented infection prior to surgical procedure of interest

Patients who expired perioperatively

Patients who had other procedures requiring general or spinal anesthesia that occurred within three days (four days for CABG or Other Cardiac Surgery) prior to or after the procedure of interest (during separate surgical episodes) during this hospital stay

Patients who were receiving antibiotics more than 24 hours prior to surgery (except colon surgery patients taking oral prophylactic antibiotics)

Patients who were receiving antibiotics within 24 hours prior to arrival (except colon surgery patients taking oral prophylactic antibiotics) Patients who did not receive any antibiotics during this hospitalization.

Patients who received urinary antiseptics only (as defined in Appendix C, Table 3.11)

Patients with Reasons to Extend Antibiotics.

Adjustment/Stratification: no risk adjustment necessary/The antibiotic prophylaxis measures are stratified according to surgery type. The tables are subsets of Table 5.10 (see link for Specification Manual and Appendix A, Tables 5.01 to 5.08. The specific procedures must be in the large table (Table 5.10) to be eligible for the SCIP measures. The measure specific tables for SCIP-Inf-3 are 5.01 to 5.08 Level of Analysis: Facility/ Agency, Population: National, Can be measured at all levels, Program: QIO Type of Measure: Process

#### 0529 Prophylactic antibiotics discontinued within 24 hours after surgery end time

Data Source: Electorinc administrative data/ claims; Electronic Health/ Medical Record; Paper medical record/ flow-sheet Most facilities use vendors to collect the data electronically. CMS provides a free, downloadable tool called CART. A paper tool modeled after the data collected electronically is provided as an attachment. CART downloads can be found on QualityNet.org at http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1138900279093 Measure Steward: Centers for Medicare & Medicaid Services | 7500 Security Boulevard , Mail Stop S3-01-02 | Baltimore | Maryland | 21244-1850

**Steering Committee Recommendation for Endorsement: Conditional** <u>Y-19; N-0; A-0</u> Pending final recommendation. **Rationale:** The measure is important and provides an appropriate timeline for discontinuing antibiotic therapy promoting appropriate use of antibiotics.

#### **Steering Committee Comments:**

This was one of four related measures considered for potential harmonization. The four included: maintenance measure 0529: Prophylactic antibiotics discontinued within 24 hours after surgery end time; endorsed measure 0637: Discontinuation of prophylactic antibiotics (cardiac procedures); maintenance measure 0128: Duration of antibiotic prophylaxis for cardiac surgery patients; and endorsed measure 0271: Discontinuation of prophylactics antibiotics (non-cardiac procedures). Discussion of the four measures is included here. The Steering Committee determined there were no competing measures in the group. Members requested that the developers evaluate the extent to which harmonization of the four measures could be accomplished. They asked that initial focus be on refining the exclusions to ensure they capture the same information and that end times of 24 and 48 hours be examined in terms of whether there are cardiac surgeries for which the different end times are specifically indicated and if so that they be specified for capture within the relevant measures. Also, members asked that the laparoscopy exclusion be removed from Measure 0128. For those measures not within the current project (AMA-PCPI measures 0637 and 0271), NQF staff will relay the requests of the Committee for their consideration as they update and test the measures.

The measure developers provided a response to the Committee's request. The developers are currently working to schedule a conference call to begin discussing harmonization or combining the antibiotic prophylaxis measures per the Committee's request. On the November 29 call, the Committee agreed to recommend measure 0529 as it currently stands with the expectation that the harmonized measure will be submitted to the next Surgery project in 2013. The Committee will vote on final recommendation for endorsement of this measure following the conference call.

1. Importance to Measure and Report: Y-19; N-0

(1a. Impact; 1b. Performance gap; 1c. Outcome or Evidence)

Rationale: The measure has a small performance gap but includes evidence that disparities among subpopulations demonstrate performance below 90 percent.

2. Scientific Acceptability of Measure Properties: C-14; P-4; M-1; N-0

(2a. Precise specifications; 2b. Reliability testing; 2c. Validity testing; 2d. Exclusions justified; 2e. Risk adjustment/stratification; 2f. Meaningful differences; 2g. Comparability; 2h. Disparities)

**Rationale:** The Committee discussed single dose prophylaxis compared with 24 hour prophylaxis and no post-operative prophylaxis noting the timeframe of this measure is standard at present. They also discussed requesting the measure's 24 hour timeframe to be changed to shorten duration when the evidence supports. The laparoscopic exclusion is removed effective January 1, 2012.

#### 3. Usability: C-18; P-1; M-0; N-0

(3a. Meaningful/useful for public reporting and quality improvement; 3b. Harmonized; 3c. Distinctive or additive value to existing measures)

Rationale: The measure is currently in use and is part of the Surgical Care Improvement Project (SCIP) measure set.

4. Feasibility: <u>C-16; P-3; M-0; N-0</u>

(4a. Clinical data generated during care process; 4b. Electronic sources; 4c. Exclusions – no additional data source; 4d. Susceptibility to inaccuracies/ unintended consequences identified 4e. Data collection strategy can be implemented) **Rationale:** The measure relies on administrative claims data.

### NQF MEMBER AND PUBLIC COMMENT

No comments were made.

### NEXT STEPS

Mrs. Forman Morgan indicated that staff would send the revised and updated composite submission form for measure 1741 to the Committee when the developer submitted the updated information. The Committee will vote via Survey Monkey on final recommendation for NQF endorsement on all measures discussed on today's call with the exception of measure 1741.

The phase I measures were approved by the CSAC and are now currently being reviewed by the Board of Directors. Final ratification is expected this week. Once the measures are ratified, the measures will go out for a 30-day appeals process. Mrs. Forman Morgan will send out the press release to the Committee once the measures have been ratified.

The phase II measures are currently in NQF Member Voting; voting will close on December 5. CSAC will review the phase II measures on their December 12 conference call. Mrs. Forman Morgan will send out the CSAC agenda to the Committee once it has been finalized.

### Table of Similar, or Competing Measures and those with potential for Harmonization

### AAA Repair

AHRQ and Leapfrog measures have similar measure focus though view differently which combines volume and mortality (i.e., mortality vs. combined volume and mortality to predict survival) and use administrative/claims data; level of analysis for both is facility.

SVS measures have a focus similar to that of the AHRQ mortality measure and use registry data. Level of analysis can be at group, individual or facility level.

|         | Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4)   | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11)   | <b>Endorsed Measure 0736:</b><br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA) | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs   | <b>New Candidate Standard</b><br><b>1534</b> : In-hospital mortality<br>following elective EVAR<br>of small AAAs   |
|---------|--|---|---|--|--|
| Status  | Currently undergoing<br>maintenance review<br>Notes: 0357 and 0359<br>reported as a pair.<br>Importance Y-10; N-11<br>related to lack of<br>stratification; vote on<br>remaining criteria<br>pending developer<br>response to requests<br>related to methods<br>changes for stratification<br>by open and EVAR and<br>RA model clarification.<br>Developer asked to meet<br>with SVS to harmonize<br>or blend AAA measures | Currently undergoing<br>maintenance review<br>Notes: 0357 and 0359<br>reported as a pair<br>Importance Y-10; N-11<br>related to lack of<br>stratification; vote on<br>remaining criteria<br>pending developer<br>response to requests<br>related to methods<br>changes for stratification<br>by open and EVAR and<br>RA model clarification.<br>Developer asked to meet<br>with SVS to harmonize or<br>blend AAA measures | Endorsed 9/2010   | Currently undergoing<br>review<br>Notes: Criteria met N-<br>11, Y-9; SC requests to<br>permit further<br>consideration addressed,<br>remaining concern<br>documentation and<br>tracking of aneurysm<br>size outside registry | Currently undergoing<br>review<br>Notes: Criteria met N-12,<br>Y-9; SC requests to permit<br>further consideration<br>addressed, remaining<br>concern documentation<br>and tracking of aneurysm<br>size outside registry |
| Steward | Agency for Healthcare<br>Research and Quality  | Agency for Healthcare<br>Research and Quality   | Leapfrog Group  | Society for Vascular<br>Surgery  | Society for Vascular<br>Surgery  |

| Description          | Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4)Count of discharges with<br>a procedure code of<br>provider-level AAA<br>repair.  | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11)<br>Percent of adult hospital<br>discharges in a one-year<br>time period with a<br>procedure code of AAA<br>repair and a diagnosis of<br>AAA with an in-hospital<br>death.                          | Endorsed Measure 0736:<br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA)<br>A reliability adjusted<br>measure of AAA repair<br>performance that<br>optimally combines two<br>important domains: AAA<br>hospital volume and<br>AAA operative mortality,<br>to provide predictions on | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs<br>Percentage of<br>asymptomatic patients<br>undergoing open repair<br>of small abdominal aortic<br>aneurysms (AAA) who<br>die while in hospital. This<br>measure is proposed for<br>both hospitals and | New Candidate Standard<br>1534: In-hospital mortality<br>following elective EVAR<br>of small AAAs<br>Percentage of patients<br>undergoing elective<br>endovascular repair of<br>small asymptomatic<br>abdominal aortic<br>aneurysms (AAA) who<br>die while in hospital. This<br>measure is proposed for |
|----------------------|---|--|---|--|---|
| Type of Measure      | Structure/management  | Outcome  | hospital AAA survival<br>rates in patients age 18<br>and over.<br>Outcome   | individual providers.<br>Outcome   | both hospitals and<br>individual providers.<br>Outcome  |
| Numerator            | Discharges, age 18 years<br>and older, with an<br>abdominal aortic<br>aneurysm repair<br>procedure and a<br>principal or secondary<br>diagnosis of AAA.<br>Time window: Time<br>window can be<br>determined by user, but<br>is generally a calendar<br>year. Note the volume-<br>outcome estimates are<br>based on one year of<br>data. | Number of deaths<br>(DISP=20) among cases<br>meeting the inclusion and<br>exclusion rules for the<br>denominator.<br>Time window: Time<br>window can be<br>determined by user, but is<br>generally a calendar year.<br>Note that the reliability<br>weights are calculated on<br>one year of data. | Survival rate for patients<br>age 18 and over without<br>AAA rupture who<br>undergo an AAA repair.<br>Time Window: During<br>the hospital admission   | Mortality following<br>elective open repair of<br>asymptomatic AAAs in<br>men with < 6 cm dia and<br>women with < 5.5 cm dia<br>AAAs.<br>Time window: Lifetime<br>for provider reporting,<br>annual for hospital<br>reporting  | Mortality following<br>elective endovascular<br>AAA repair of<br>asymptomatic AAAs in<br>men with < 6 cm dia and<br>women with < 5.5 cm dia<br>AAAs.<br>Time window: Lifetime<br>for provider reporting,<br>annual for hospital<br>reporting  |
| Numerator<br>Details | Discharges, age 18 years<br>and older, with an<br>abdominal aortic  | Number of deaths<br>(DISP=20) among cases<br>meeting the inclusion and   | For the observed<br>mortality, the hospital<br>submits the observed   | ANY registry that<br>includes hospitalization<br>details, AAA diameter   | A registry that includes<br>hospitalization details,<br>AAA diameter and  |

| Maintenance Measure   | Maintenance Measure                  | Endorsed Measure 0736:  | New Candidate   | New Candidate Standard   |
|---|--------------------------------------|---|---|--|
| 0357: Abdominal aortic  | 0359: Abdominal aortic               | Survival predictor for  | Standard 1523: In-  | <b>1534</b> : In-hospital mortality  |
| aneurysm (AAA) repair   | artery (AAA) repair                  | abdominal aortic  | hospital mortality  | following elective EVAR  |
| volume (IQI 4)  | mortality rate (IQI 11)              | aneurysm (AAA)  | following elective open<br>repair of small AAAs   | of small AAAs  |
| aneurysm repair<br>procedure and a<br>principal or secondary<br>diagnosis of AAA in any<br> | exclusion rules for the denominator. | deaths for AAA cases in<br>patients without rupture<br>as identified using the<br>denominator and<br>exclusion codes. | repair of small AAAs<br>and discharge status is<br>required to identify<br>patients for numerator<br>inclusion. The Society for<br>Vascular Surgery<br>Vascular Quality<br>Initiative (SVS VQI) and<br>the Vascular Study<br>Group of New England<br>(VSGNE) are examples of<br>registries that record such<br>information but the<br>measure is not limited to<br>these registries. Patients<br>who died in hospital<br>following elective open<br>infrarenal AAA repair if<br>their aneurysm was<br>asymptomatic and small<br>(< 6cm dia in men, <5.5<br>cm dia in women, judged<br>by preoperative imaging<br>(CT, MR or ultrasound)). | discharge status is<br>required to identify<br>patients for numerator<br>inclusion. The Society for<br>Vascular Surgery Vascular<br>Quality Initiative (SVS<br>VQI) and the Vascular<br>Study Group of New<br>England (VSGNE)<br>registries records such<br>information. Patients who<br>died in hospital following<br>endovascular infrarenal<br>AAA repair (EVAR) if<br>their asymptomatic<br>aneurysm was repaired<br>electively and was<br>asymptomatic and small<br>(< 6cm dia in men, <5.5<br>cm dia in women, judged<br>by preoperative imaging<br>(CT, MR or ultrasound)). |
| childbirth, and   |                                      |   |   |  |

|                                      | Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4)<br>puerperium) | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11)  | <b>Endorsed Measure 0736:</b><br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA)   | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs  | <b>New Candidate Standard</b><br><b>1534</b> : In-hospital mortality<br>following elective EVAR<br>of small AAAs  |
|--------------------------------------|---|--|---|---|---|
| Denominator                          | N/A   | Discharges, age 18 years<br>and older, with ICD-9-CM<br>AAA repair code<br>procedure and a diagnosis<br>of AAA in any field. The<br>denominator may be<br>stratified by open vs.<br>endovascular procedures,<br>and ruptured vs. un-<br>ruptured AAA.  | All hospital patients age<br>18 and over without<br>rupture who had an AAA<br>repair.<br>Time Window: 12 months   | All elective open repairs<br>of asymptomatic AAAs<br>in men with < 6 cm dia<br>and women with < 5.5 cm<br>dia AAAs.<br>Time window: Lifetime<br>for provider reporting,<br>annual for hospital<br>reporting   | All elective endovascular<br>repairs of asymptomatic<br>AAAs in men with < 6 cm<br>dia and women with < 5.5<br>cm dia AAAs.<br>Time window: Lifetime<br>for provider reporting,<br>annual for hospital<br>reporting   |
| Denominator                          | Female, Male; 18 and  | Time window: Time<br>window can be<br>determined by user, but is<br>generally a calendar year.<br>Female, Male; 18 and older   |   | Female, Male; 18 years or   | Female, Male; 18 years or   |
| Categories<br>Denominator<br>Details | older<br>N/A  | Discharges, age 18 years<br>and older, with ICD-9-CM<br>AAA repair code<br>procedure and a diagnosis<br>of AAA in any field. The<br>denominator may be<br>stratified by open vs.<br>endovascular procedures,<br>and ruptured vs. un-<br>ruptured AAA.<br>ICD-9-CM AAA repair<br>procedure codes: | For the volume predicted<br>mortality, hospitals count<br>the number of all AAA<br>repair cases using the<br>following procedure<br>codes.<br>ICD-9-CM Procedure<br>Codes for AAA repair<br>3834 Aorta Resection &<br>Anast<br>3844 Resection<br>Abdominal Aorta with | older<br>ANY registry that<br>includes hospitalization<br>details, AAA diameter<br>and discharge status is<br>required to identify<br>patients for denominator<br>inclusion. The Society for<br>Vascular Surgery<br>Vascular Surgery<br>Vascular Quality<br>Initiative (SVS VQI) and<br>the Vascular Study<br>Group of New England<br>(VSGNE) are examples of | older<br>A registry that includes<br>hospitalization details,<br>AAA diameter and<br>discharge status is<br>required to identify<br>patients for denominator<br>inclusion. The Society for<br>Vascular Surgery Vascular<br>Quality Initiative (SVS<br>VQI) and the Vascular<br>Study Group of New<br>England (VSGNE)<br>registries records such |

| Maintenance Measu0357: Abdominal aor |  | <b>Endorsed Measure 0736:</b><br>Survival predictor for   | New Candidate<br>Standard 1523: In-  | New Candidate Standard<br>1534: In-hospital mortality  |
|--------------------------------------|--|---|--|--|
| aneurysm (AAA) rep<br>volume (IQI 4) | air artery (AAA) repair<br>mortality rate (IQI 11)   | abdominal aortic<br>aneurysm (AAA)  | hospital mortality<br>following elective open<br>repair of small AAAs  | following elective EVAR<br>of small AAAs   |
|                                      | <ul> <li>3834</li> <li>AORTA RESECTION &amp; ANAST</li> <li>3844</li> <li>RESECT ABDM AORTA</li> <li>W REPL</li> <li>3864</li> <li>EXCISION OF AORTA</li> <li>3971</li> <li>ENDO IMPLANT OF</li> <li>GRAFT IN AORTA</li> <li>ICD-9-CM AAA diagnosis</li> <li>codes:</li> <li>4413</li> <li>RUPT ABD AORTIC</li> <li>ANEURYSM</li> <li>4414</li> <li>ABDOM AORTIC</li> <li>ANEURYSM</li> <li>Exclude cases:</li> <li>missing discharge</li> <li>disposition</li> <li>(DISP=missing), gender</li> <li>(SEX=missing), quarter</li> <li>(DQTR=missing), year</li> <li>(YEAR=missing) or</li> <li>principal diagnosis (DX1</li> <li>=missing)</li> <li>transferring to another</li> </ul> | replacement<br>3864 Excision of aorta<br>3925 Aorta-iliac-femoral<br>bypass<br>3971 Endo Implant of<br>Graft in Aorta<br>For the observed<br>mortality hospitals count<br>the number of AAA<br>repair cases that also<br>have a diagnosis of<br>unruptured AAA using<br>the following codes.<br>ICD-9CM Codes for AAA<br>without rupture<br>441.4 Dissection of aorta<br>aneurysm unspecified<br>site<br>441.7 Thoracoabdominal<br>aneurysm without<br>rupture<br>441.9 Aortic aneurysm of<br>unspecified site without<br>rupture | registries that record such<br>information but the<br>measure is not limited to<br>these registries. Patients<br>who underwent elective<br>open AAA repair are<br>included if their<br>aneurysm was<br>asymptomatic and small<br>(< 6cm dia in men, <5.5<br>cm dia in women, judged<br>by preoperative imaging<br>(CT, MR or ultrasound)). | information. Patients who<br>underwent endovascular<br>AAA repair are included<br>if their aneurysm was<br>asymptomatic and small<br>(< 6cm dia in men, <5.5<br>cm dia in women, judged<br>by preoperative imaging). |

|                   | Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4) | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11)   | Endorsed Measure 0736:<br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA)   | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs   | New Candidate Standard<br>1534: In-hospital mortality<br>following elective EVAR<br>of small AAAs  |
|-------------------|--|---|--|--|--|
|                   |  | <ul> <li>short-term hospital<br/>(DISP=2)</li> <li>MDC 14 (pregnancy,<br/>childbirth, and<br/>puerperium)</li> </ul>  |  |  |  |
| Exclusions        | Numerator exclusions<br>• MDC 14 (pregnancy,<br>childbirth, and<br>puerperium)           | <ul> <li>Exclude cases:</li> <li>missing discharge<br/>disposition</li> <li>(DISP=missing), gender</li> <li>(SEX=missing), age</li> <li>(AGE=missing), quarter</li> <li>(DQTR=missing), quarter</li> <li>(DQTR=missing) or</li> <li>principal diagnosis (DX1<br/>=missing)</li> <li>transferring to another</li> <li>short-term hospital</li> <li>(DISP=2)</li> <li>MDC 14 (pregnancy,<br/>childbirth, and<br/>puerperium)</li> </ul> | Patients with ruptured<br>aneurysm or<br>thoracoabdominal<br>aneurysms.  | > 6 cm minor diameter -<br>men<br>> 5.5 cm minor diameter -<br>women<br>Symptomatic AAAs that<br>required<br>urgent/emergent (non-<br>elective) repair | > 6 cm diameter - men<br>> 5.5 cm diameter -<br>women<br>Symptomatic AAAs that<br>required urgent/emergent<br>(non-elective) repair        |
| Exclusion Details | This volume measure<br>does not have a<br>denominator.                                   | <ul> <li>Exclude cases:</li> <li>missing discharge disposition</li> <li>(DISP=missing), gender</li> <li>(SEX=missing), age</li> <li>(AGE=missing), quarter</li> <li>(DQTR=missing), year</li> <li>(YEAR=missing) or principal diagnosis (DX1 =missing)</li> <li>transferring to another</li> </ul>  | For the count of all AAA<br>procedures exclude:<br>3845 Thoracoabdominal<br>procedures.<br>For the observed<br>mortality domain,<br>exclude all Thoracic<br>Diagnosis Codes and<br>dissection codes for AAA<br>441.0x General code | Patients undergoing non-<br>elective open repair of<br>symptomatic AAAs or<br>those with AAAs larger<br>than the diameters noted<br>above.             | Patients undergoing non-<br>elective open repair of<br>symptomatic AAAs or<br>those with AAAs larger<br>than the diameters noted<br>above. |

|                 | Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4) | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11)   | <b>Endorsed Measure 0736:</b><br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA)  | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs | <b>New Candidate Standard</b><br><b>1534</b> : In-hospital mortality<br>following elective EVAR<br>of small AAAs |
|-----------------|--|---|--|--|--|
|                 |  | short-term hospital<br>(DISP=2)<br>• MDC 14 (pregnancy,<br>childbirth, and<br>puerperium)   | 441.1 Thoracic aneurysm<br>ruptured<br>441.2 Thoracic aneurysm<br>without rupture<br>441.3 Abdominal<br>aneurysm ruptured<br>441.5 Aortic aneurysm of<br>unspecified site ruptured<br>441.6 Thoracoabdominal<br>aneurysm ruptured.<br>Mortality Domain does<br>excludes thoracic<br>aneurysm Procedure<br>Code:<br>38.45 Resection of vessel<br>with replacement, other<br>thoracic vessels. |  |  |
| Risk Adjustment | No risk adjustment<br>necessary  | Risk adjustment method<br>widely or commercially<br>available. The predicted<br>value for each case is<br>computed using a<br>hierarchical model<br>(logistic regression with<br>hospital random effect)<br>and covariates for gender,<br>age in years (in 5-year age<br>groups), All Patient<br>Refined-Diagnosis Related<br>Group (APR-DRG) and<br>APR-DRG risk-of- | We used an empirical<br>Bayes approach to<br>combine mortality rates<br>with information on<br>hospital volume at each<br>hospital. In traditional<br>empirical Bayes methods,<br>a point estimate (e.g.,<br>mortality rate observed at<br>a hospital) is adjusted for<br>reliability by shrinking it<br>towards the overall mean<br>(e.g., overall mortality<br>rate in the population).    | No risk adjustment<br>necessary  | No risk adjustment<br>necessary  |

| Maintenance Measure    | Maintenance Measure          | Endorsed Measure 0736:     | New Candidate           | New Candidate Standard              |
|------------------------|------------------------------|----------------------------|-------------------------|-------------------------------------|
| 0357: Abdominal aortic | 0359: Abdominal aortic       | Survival predictor for     | Standard 1523: In-      | <b>1534</b> : In-hospital mortality |
| aneurysm (AAA) repair  | artery (AAA) repair          | abdominal aortic           | hospital mortality      | following elective EVAR             |
| volume (IQI 4)         | mortality rate (IQI 11)      | aneurysm (AAA)             | following elective open | of small AAAs                       |
|                        |                              |                            | repair of small AAAs    |                                     |
|                        | mortality subclass. The      | We modified this           |                         |                                     |
|                        | reference population used    | traditional approach by    |                         |                                     |
|                        | in the model is the          | shrinking the observed     |                         |                                     |
|                        | universe of discharges for   | mortality rate back        |                         |                                     |
|                        | states that participate in   | toward the mortality rate  |                         |                                     |
|                        | the HCUP State Inpatient     | expected given the         |                         |                                     |
|                        | Databases (SID) for the      | volume at that hospital –  |                         |                                     |
|                        | year 2007 (updated           | we refer to this as the    |                         |                                     |
|                        | annually), a database        | "volume-predicted          |                         |                                     |
|                        | consisting of 43 states and  | mortality". With this      |                         |                                     |
|                        | approximately 30 million     | approach, the observed     |                         |                                     |
|                        | adult discharges. The        | mortality rate is weighted |                         |                                     |
|                        | expected rate is computed    | according to how reliably  |                         |                                     |
|                        | as the sum of the            | it is estimated, with the  |                         |                                     |
|                        | predicted value for each     | remaining weight placed    |                         |                                     |
|                        | case divided by the          | on the information         |                         |                                     |
|                        | number of cases for the      | regarding hospital         |                         |                                     |
|                        | unit of analysis of interest | volume [volume-            |                         |                                     |
|                        | (i.e., hospital, state, and  | predicted mortality].      |                         |                                     |
|                        | region). The risk adjusted   |                            |                         |                                     |
|                        | rate is computed using       | Risk adjustment for        |                         |                                     |
|                        | indirect standardization as  | patient characteristics is |                         |                                     |
|                        | the observed rate divided    | not used because in        |                         |                                     |
|                        | by the expected rate,        | sensitivity analysis,      |                         |                                     |
|                        | multiplied by the            | composite measures         |                         |                                     |
|                        | reference population rate.   | based on an unadjusted     |                         |                                     |
|                        | Risk adjustment factors:     | mortality input and a      |                         |                                     |
|                        | sex                          | risk-adjusted mortality    |                         |                                     |
|                        | age 18-24; age 25-29; age    | input had a correlation of |                         |                                     |
|                        | 30-34; age 35-39; age 40-44; | (.95) and thus were        |                         |                                     |
|                        | age 45-49; age 50-54; age    | equally good at            |                         |                                     |
|                        | 55-59; age 60-64; age 65-69; | predicting future          |                         |                                     |

| Maintenance Measure    | Maintenance Measure   | Endorsed Measure 0736:  | New Candidate                                   | New Candidate Standard              |
|------------------------|---|---|---|-------------------------------------|
| 0357: Abdominal aortic | 0359: Abdominal aortic  | Survival predictor for  | Standard 1523: In-                              | <b>1534</b> : In-hospital mortality |
| aneurysm (AAA) repair  | artery (AAA) repair   | abdominal aortic  | hospital mortality                              | following elective EVAR             |
| volume (IQI 4)         | mortality rate (IQI 11)   | aneurysm (AAA)  | following elective open<br>repair of small AAAs | of small AAAs                       |
|                        | age 70-74; age 75-79; age<br>80-84; age 85+   | performance.  |   |                                     |
|                        | each age category*female<br>ADRG 1731 (other<br>vascular procedures-                | The formula for<br>calculating the survival<br>predictor has two  |   |                                     |
|                        | minor)<br>ADRG 1732 (other<br>vascular procedures-<br>moderate)<br>ADRG 1733 (other | components, one is a<br>volume predicted<br>mortality rate, and the<br>second is an observed<br>mortality rate. |   |                                     |
|                        | vascular procedures-<br>major)  | The volume predicted  |   |                                     |
|                        | ADRG 1734 (other  | mortality rate reflects the   |   |                                     |
|                        | vascular procedures-  | hospitals experience  |   |                                     |
|                        | extreme)  | performing AAA  |   |                                     |
|                        | ADRG 1691 (major  | surgeries (thus, it   |   |                                     |
|                        | thoracic and abdominal  | includes all AAA  |   |                                     |
|                        | vascular procedures-  | surgeries) and uses   |   |                                     |
|                        | minor)  | mortality for all hospitals   |   |                                     |
|                        | ADRG 1692 (major  | at that specific volume to  |   |                                     |
|                        | thoracic and abdominal  | create the volume   |   |                                     |
|                        | vascular procedures-  | predicted mortality. The  |   |                                     |
|                        | moderate)   | input data from the   |   |                                     |
|                        | ADRG 1693 (major  | hospitals for this domain   |   |                                     |
|                        | thoracic and abdominal  | is a volume count of all  |   |                                     |
|                        | vascular procedures-  | AAAs performed in the   |   |                                     |
|                        | major)  | hospital.   |   |                                     |
|                        | ADRG 1694 (major  |   |   |                                     |
|                        | thoracic and abdominal  | The second domain is the  |   |                                     |
|                        | vascular procedures-  | observed mortality, for   |   |                                     |
|                        | extreme   | this domain the   |   |                                     |
|                        | ADRG 9999 (other)   | population is the group   |   |                                     |

| Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4) | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11) | <b>Endorsed Measure 0736:</b><br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA)   | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs | <b>New Candidate Standard</b><br><b>1534</b> : In-hospital mortality<br>following elective EVAR<br>of small AAAs |
|--|---|---|--|--|
|  | MDC 5 (cardiovascular)<br>Transfer-in-status  | of AAA cases without<br>rupture, the data needed<br>for this domain is the<br>number of observed<br>deaths occurring for<br>AAA cases without<br>rupture, within the<br>inpatient setting.The general composite<br>measure calculation is as<br>follows:<br>Predicted Survival = 1-<br>Predicted MortalityPredicted Mortality =<br>(weight)*(mortality) + (1-<br>weight)*(volume<br>predicted mortality)Volume predicted<br>mortality* = intercept -<br>coefficient*ln(caseload),<br>where the intercepts and<br>coefficients are derived<br>from regression using the<br>NIS data and the caseload<br>comes from the Leapfrog<br>Hospital Survey (answer<br>to question #1 for each<br>high-risk procedure).<br>*Any negative values are |  |  |

| Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4) | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11) | <b>Endorsed Measure 0736:</b><br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA)   | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs | <b>New Candidate Standard</b><br><b>1534</b> : In-hospital mortality<br>following elective EVAR<br>of small AAAs |
|--|---|---|--|--|
|  |   | reset to "0"Weight = mortality<br>signal/(mortality signal +<br>[mortality signal and<br>sigma / caseload]), where<br>mortality signal and<br>sigma are derived from<br>the NIS data and the<br>caseload comes from the<br>Leapfrog Hospital Survey<br>(answer to question #1<br>for each high-risk<br>procedure).Method: We used an<br>empirical Bayes approach<br>to combine mortality<br>rates with information on<br>hospital. In traditional<br>empirical Bayes methods,<br>a point estimate (e.g.,<br>mortality rate observed at<br>a hospital) is adjusted for<br>reliability by shrinking it<br>towards the overall mean<br>(e.g., overall mortality<br>rate in the population).<br>We modified this<br>traditional approach by<br>shrinking the observed |  |  |

| 035<br>ane | <b>intenance Measure</b><br>7: Abdominal aortic<br>eurysm (AAA) repair<br>ume (IQI 4) | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11) | <b>Endorsed Measure 0736:</b><br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA)   | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs | <b>New Candidate Standard</b><br><b>1534</b> : In-hospital mortality<br>following elective EVAR<br>of small AAAs |
|------------|---|---|---|--|--|
|            |   |   | mortality rate back<br>toward the mortality rate<br>expected given the<br>volume at that hospital —<br>we refer to this as the<br>"volume-predicted<br>mortality". With this<br>approach, the observed<br>mortality rate is weighted<br>according to how reliably<br>it is estimated, with the<br>remaining weight placed<br>on the information<br>regarding hospital<br>volume [volume-<br>predicted mortality].<br>Risk adjustment for<br>patient characteristics is<br>not used because in<br>sensitivity analysis,<br>composite measures<br>based on an unadjusted<br>mortality input and a<br>risk-adjusted mortality<br>input had a correlation of<br>(.95) and thus were<br>equally good at<br>predicting future<br>performance. |  |  |

| Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4) | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11) | <b>Endorsed Measure 0736:</b><br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA)  | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs | <b>New Candidate Standard</b><br><b>1534</b> : In-hospital mortality<br>following elective EVAR<br>of small AAAs |
|--|---|--|--|--|
|  |   | calculating the survival<br>predictor has two<br>components, one is a<br>volume predicted<br>mortality rate, and the<br>second is an observed<br>mortality rate.   |  |  |
|  |   | The volume predicted<br>mortality rate reflects the<br>hospitals experience<br>performing AAA<br>surgeries (thus, it<br>includes all AAA<br>surgeries) and uses<br>mortality for all hospitals<br>at that specific volume to<br>create the volume<br>predicted mortality. The<br>input data from the |  |  |
|  |   | <ul> <li>hospitals for this domain<br/>is a volume count of all<br/>AAAs performed in the<br/>hospital.</li> <li>The second domain is the<br/>observed mortality, for<br/>this domain the<br/>population is the group<br/>of AAA cases without<br/>rupture, the data needed</li> </ul>               |  |  |

| Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4) | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11) | <b>Endorsed Measure 0736:</b><br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA)   | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs | <b>New Candidate Standard</b><br><b>1534</b> : In-hospital mortality<br>following elective EVAR<br>of small AAAs |
|--|---|---|--|--|
|  |   | number of observed<br>deaths occurring for<br>AAA cases without<br>rupture, within the<br>inpatient setting.The general composite<br>measure calculation is as<br>follows:<br>Predicted Survival = 1-<br>Predicted MortalityPredicted Mortality =<br>(weight)*(mortality) + (1-<br>weight)*(volume<br>predicted mortality)Volume predicted<br>mortality* = intercept -<br>coefficient*ln(caseload),<br>where the intercepts and<br>coefficients are derived<br>from regression using the<br>NIS data and the caseload<br>comes from the Leapfrog<br>Hospital Survey (answer<br>to question #1 for each<br>high-risk procedure).<br>*Any negative values are<br>reset to "0" |  |  |
|  |   | Weight = mortality  |  |  |

|                | Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4)   | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11)   | <b>Endorsed Measure 0736:</b><br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA)   | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs | New Candidate Standard<br>1534: In-hospital mortality<br>following elective EVAR<br>of small AAAs |
|----------------|--|---|---|--|---|
|                |  |   | signal/(mortality signal +<br>[mortality<br>sigma/caseload]), where<br>mortality signal and<br>sigma are derived from<br>the NIS data and the<br>caseload comes from the<br>Leapfrog Hospital Survey<br>(answer to question #1<br>for each high-risk<br>procedure). |  |   |
| Stratification | The stratification of the<br>denominator for open vs.<br>endovascular and<br>ruptured vs. unruptured<br>involve the following<br>codes in the denominator<br>specification:<br>Abdominal Aortic<br>Aneurysm Repair<br>(PRAAAR)<br>Volume Indicator<br>IQI #4<br>Mortality (post-op)<br>Indicator<br>IQI #11<br>AAA Repair<br>ICD-9-CM Procedure<br>Codes:<br>PROC FORMAT;<br>OPEN<br>VALUE \$PRAAARP | Gender, age (5-year age<br>groups), race / ethnicity,<br>primary payer, custom<br>The stratification of the<br>denominator for open vs.<br>endovascular and<br>ruptured vs. unruptured<br>involves the following<br>codes in the denominator<br>specification:<br>Abdominal Aortic<br>Aneurysm Repair<br>(PRAAAR)<br>Volume Indicator / IQI #4<br>Mortality (post-op)<br>Indicator / IQI #11<br>AAA Repair<br>ICD-9-CM Procedure<br>Codes:<br>PROC FORMAT |   | N/A  | N/A   |

| <br>Maintenance Measure      | Maintenance Measure          | Endorsed Measure 0736: | New Candidate           | New Candidate Standard      |
|------------------------------|------------------------------|------------------------|-------------------------|-----------------------------|
| 0357: Abdominal aortic       | 0359: Abdominal aortic       | Survival predictor for | Standard 1523: In-      | 1534: In-hospital mortality |
| aneurysm (AAA) repair        | artery (AAA) repair          | abdominal aortic       | hospital mortality      | following elective EVAR     |
| volume (IQI 4)               | mortality rate (IQI 11)      | aneurysm (AAA)         | following elective open | of small AAAs               |
|                              |                              |                        | repair of small AAAs    |                             |
| 3834 = 1 / AORTA             | OPEN                         |                        |                         |                             |
| <b>RESECTION &amp; ANAST</b> | VALUE \$PRAAARP              |                        |                         |                             |
| 3844 = 1 / RESECT            | 3834 = 1 / AORTA             |                        |                         |                             |
| ABDM AORTA W REPL            | <b>RESECTION &amp; ANAST</b> |                        |                         |                             |
| 3864 = 1 / EXCISION OF       | 3844 = 1 / RESECT ABDM       |                        |                         |                             |
| AORTA/                       | AORTA W REPL                 |                        |                         |                             |
| OTHER = 0                    | 3864 = 1 / EXCISION OF       |                        |                         |                             |
| ENDOVASCULAR                 | AORTA/                       |                        |                         |                             |
| VALUE \$PRAAA2P              | OTHER = 0                    |                        |                         |                             |
| 3971= 1 /ENDO IMPL           | ENDOVASCULAR                 |                        |                         |                             |
| GRFT ABD AORTA/              | VALUE \$PRAAA2P              |                        |                         |                             |
| OTHER = 0                    | 3971 = 1/ENDO IMPL           |                        |                         |                             |
| Include Only: AAA            | GRFT ABD AORTA/              |                        |                         |                             |
| ICD-9-CM Diagnosis           | OTHER = 0                    |                        |                         |                             |
| Codes:                       | Include Only: AAA            |                        |                         |                             |
| RUPTURED                     | ICD-9-CM Diagnosis           |                        |                         |                             |
| VALUE \$PRAAARD              | Codes:                       |                        |                         |                             |
| 4413 = 1 / RUPT ABD          | RUPTURED                     |                        |                         |                             |
| AORTIC ANEURYSM /            | VALUE \$PRAAARD              |                        |                         |                             |
| OTHER = 0                    | 4413 = 1 / RUPT ABD          |                        |                         |                             |
| UNRUPTURED                   | AORTIC ANEURYSM/             |                        |                         |                             |
| VALUE \$PRAAA2D              | OTHER = 0                    |                        |                         |                             |
| 4414 = 1 / ABDOM             | UNRUPTURED                   |                        |                         |                             |
| AORTIC ANEURYSM /            | VALUE \$PRAAA2D              |                        |                         |                             |
| OTHER = 0                    | 4414 = 1 / ABDOM             |                        |                         |                             |
|                              | AORTIC ANEURYSM/             |                        |                         |                             |
| The following analytic       | OTHER = 0                    |                        |                         |                             |
| results were achieved        |                              |                        |                         |                             |
| with the specification       | The following analytic       |                        |                         |                             |
| modification:                | results were achieved with   |                        |                         |                             |
|                              | the specification            |                        |                         |                             |
| Table 1. Reference           | modification:                |                        |                         |                             |

| <br>Maintenance Measure | Maintenance Measure         | Endorsed Measure 0736: | New Candidate           | New Candidate Standard              |
|-------------------------|-----------------------------|------------------------|-------------------------|-------------------------------------|
| 0357: Abdominal aortic  | 0359: Abdominal aortic      | Survival predictor for | Standard 1523: In-      | <b>1534</b> : In-hospital mortality |
| aneurysm (AAA) repair   | artery (AAA) repair         | abdominal aortic       | hospital mortality      | following elective EVAR             |
| volume (IQI 4)          | mortality rate (IQI 11)     | aneurysm (AAA)         | following elective open | of small AAAs                       |
|                         |                             |                        | repair of small AAAs    |                                     |
| Population Rate and     |                             |                        |                         |                                     |
| Volume                  | Table 1. Reference          |                        |                         |                                     |
| Open, Ruptured Open,    | Population Rate and         |                        |                         |                                     |
| Un-ruptured             | Volume Open, Ruptured       |                        |                         |                                     |
| Endovascular,           | Open, Un-ruptured           |                        |                         |                                     |
| Ruptured Endovascular,  | Endovascular, Ruptured      |                        |                         |                                     |
| Un-ruptured Original    | Endovascular, Un-           |                        |                         |                                     |
| (Composite)             | ruptured                    |                        |                         |                                     |
| Population Rate         | Original(Composite)         |                        |                         |                                     |
| 2004 39.04% 4.43%       | Population Rate             |                        |                         |                                     |
| 29.11% 1.05% 6.09%      | 2004 39.04% 4.43% 29.11%    |                        |                         |                                     |
| 2005 41.10% 4.45%       | 1.05% 6.09%                 |                        |                         |                                     |
| 28.06% 1.03% 5.76%      | 2005 41.10% 4.45% 28.06%    |                        |                         |                                     |
| 2006 41.11% 4.53%       | 1.03% 5.76%                 |                        |                         |                                     |
| 29.18% 0.93% 5.22%      | 2006 41.11% 4.53% 29.18%    |                        |                         |                                     |
| 2007 39.77% 4.48%       | 0.93% 5.22%                 |                        |                         |                                     |
| 24.84% 1.16% 4.88%      | 2007 39.77% 4.48% 24.84%    |                        |                         |                                     |
| 2008 38.27% 4.82%       | $1.16\% \ 4.88\%$           |                        |                         |                                     |
| 27.17% 1.02% 4.61%      | 2008 38.27% 4.82% 27.17%    |                        |                         |                                     |
| %Change -2.0% 8.5% -    | 1.02% 4.61%                 |                        |                         |                                     |
| 6.9% -2.9% -27.9%       | %Change -2.0% 8.5% -6.9%    |                        |                         |                                     |
| Volume                  | -2.9% -27.9%                |                        |                         |                                     |
| 2004 3,241 15,723 456   | Volume                      |                        |                         |                                     |
| 17,438 36,768           | 2004 3,241 15,723 456       |                        |                         |                                     |
| 2005 2,876 12,941 568   | 17,438 36,768               |                        |                         |                                     |
| 19,981 36,292           | 2005 2,876 12,941 568       |                        |                         |                                     |
| 2006 2,652 11,152 647   | 19,981 36,292               |                        |                         |                                     |
| 22,778 37,156           | 2006 2,652 11,152 647       |                        |                         |                                     |
| 2007 2,445 9,693 799    | 22,778 37,156               |                        |                         |                                     |
| 25,101 37,970           | 2007 2,445 9,693 799 25,101 |                        |                         |                                     |
| 2008 2,352 8,851 1,068  | 37,970                      |                        |                         |                                     |
| 28,103 40,293           | 2008 2,352 8,851 1,068      |                        |                         |                                     |

| Maintenance Measure       | Maintenance Measure        | Endorsed Measure 0736: | New Candidate           | New Candidate Standard              |
|---------------------------|----------------------------|------------------------|-------------------------|-------------------------------------|
| 0357: Abdominal aortic    | 0359: Abdominal aortic     | Survival predictor for | Standard 1523: In-      | <b>1534</b> : In-hospital mortality |
| aneurysm (AAA) repair     | artery (AAA) repair        | abdominal aortic       | hospital mortality      | following elective EVAR             |
| volume (IQI 4)            | mortality rate (IQI 11)    | aneurysm (AAA)         | following elective open | of small AAAs                       |
|                           |                            |                        | repair of small AAAs    |                                     |
| %Change -32.1% -57.5%     | 28,103 40,293              |                        |                         |                                     |
| 85.1% 47.7% 9.2%          | %Change -32.1% -57.5%      |                        |                         |                                     |
| Source: State Inpatient   | 85.1% 47.7% 9.2%           |                        |                         |                                     |
| Databases (SID),          | Source: State Inpatient    |                        |                         |                                     |
| Healthcare Cost and       | Databases (SID),           |                        |                         |                                     |
| Utilization Project       | Healthcare Cost and        |                        |                         |                                     |
| (HCUP)                    | Utilization Project (HCUP) |                        |                         |                                     |
| Table 2. Hospital         | Table 2. Hospital          |                        |                         |                                     |
| Discrimination, 2008      | Discrimination, 2008       |                        |                         |                                     |
| Open, Ruptured Open,      | Open, Ruptured Open,       |                        |                         |                                     |
| Un-ruptured               | Un-ruptured                |                        |                         |                                     |
| Endovascular,             | Endovascular, Ruptured     |                        |                         |                                     |
| Ruptured Endovascular,    | Endovascular,              |                        |                         |                                     |
| Un-ruptured Original      | Un-ruptured                |                        |                         |                                     |
| (Composite)               | Original(Composite)        |                        |                         |                                     |
| Hospitals 1,015 1,343 507 | Hospitals 1,015 1,343 507  |                        |                         |                                     |
| 1,439 1,711               | 1,439 1,711                |                        |                         |                                     |
| Best Performing 24.74%    | Best Performing 24.74%     |                        |                         |                                     |
| 10.20% 12.91% 0.00%       | 10.20% 12.91% 0.00%        |                        |                         |                                     |
| 4.64%                     | 4.64%                      |                        |                         |                                     |
| Worst Performing 26.53%   | Worst Performing 26.53%    |                        |                         |                                     |
| 24.26% 39.11% 0.75%       | 24.26% 39.11% 0.75%        |                        |                         |                                     |
| 5.52%                     | 5.52%                      |                        |                         |                                     |
| 5th 32.15% 2.25% 20.14%   | 5th 32.15% 2.25% 20.14%    |                        |                         |                                     |
| 0.16% 3.02%               | 0.16% 3.02%                |                        |                         |                                     |
| 10th 33.42% 2.67%         | 10th 33.42% 2.67% 21.52%   |                        |                         |                                     |
| 21.52% 0.24% 3.32%        | 0.24% 3.32%                |                        |                         |                                     |
| 25th 35.60% 3.49%         | 25th 35.60% 3.49% 23.98%   |                        |                         |                                     |
| 23.98% 0.46% 3.86%        | 0.46% 3.86%                |                        |                         |                                     |
| Median 38.14% 4.59%       | Median 38.14% 4.59%        |                        |                         |                                     |

| Maintenance Measure        | Maintenance Measure                | Endorsed Measure 0736: | New Candidate           | New Candidate Standard              |
|----------------------------|------------------------------------|------------------------|-------------------------|-------------------------------------|
| 0357: Abdominal aortic     | 0359: Abdominal aortic             | Survival predictor for | Standard 1523: In-      | <b>1534</b> : In-hospital mortality |
| aneurysm (AAA) repair      | artery (AAA) repair                | abdominal aortic       | hospital mortality      | following elective EVAR             |
| volume (IQI 4)             | mortality rate (IQI 11)            | aneurysm (AAA)         | following elective open | of small AAAs                       |
|                            |                                    |                        | repair of small AAAs    |                                     |
| 26.91% 0.84% 4.53%         | 26.91% 0.84% 4.53%                 |                        |                         |                                     |
| 75th 40.79% 5.90%          | 75th 40.79% 5.90% 30.08%           |                        |                         |                                     |
| 30.08% 1.39% 5.27%         | 1.39% 5.27%                        |                        |                         |                                     |
| 90th 43.28% 7.27%          | 90th 43.28% 7.27% 33.14%           |                        |                         |                                     |
| 33.14% 2.04% 6.00%         | 2.04% 6.00%                        |                        |                         |                                     |
| 95th 44.82% 8.18%          | 95th 44.82% 8.18% 35.06%           |                        |                         |                                     |
| 35.06% 2.52% 6.47%         | 2.52% 6.47%                        |                        |                         |                                     |
| Source: State Inpatient    | Source: State Inpatient            |                        |                         |                                     |
| Databases (SID),           | Databases (SID),                   |                        |                         |                                     |
| Healthcare Cost and        | Healthcare Cost and                |                        |                         |                                     |
| Utilization Project        | Utilization Project                |                        |                         |                                     |
| (HCUP). Best performing    | (HCUP). Best performing            |                        |                         |                                     |
| is below the median at     | is below the median at             |                        |                         |                                     |
| 95% probability; worst     | 95% probability; worst             |                        |                         |                                     |
| performing is above the    | performing is above the            |                        |                         |                                     |
| median at 95%              | median at 95% probability.         |                        |                         |                                     |
| probability.               |                                    |                        |                         |                                     |
|                            | Table 2A. Model                    |                        |                         |                                     |
| Table 2A. Model            | Covariates, 2008                   |                        |                         |                                     |
| Covariates, 2008           | Open, Ruptured Open,               |                        |                         |                                     |
| Open, Ruptured Open,       | Un-ruptured                        |                        |                         |                                     |
| Un-ruptured                | Endovascular, Rupture              |                        |                         |                                     |
| Endovascular,              | Endovascular, Rupture              |                        |                         |                                     |
| Ruptured Endovascular,     | Un-ruptured                        |                        |                         |                                     |
| Un-ruptured Original       | Original(Composite)                |                        |                         |                                     |
| (Composite)                | Frequency                          |                        |                         |                                     |
|                            | 1 1                                |                        |                         |                                     |
| Frequency                  | N 2,284 8,729 1,038 27,989         |                        |                         |                                     |
| N 2,284 8,729 1,038 27,989 | 39,963<br>Estado 22 E% 27 2% 21 E% |                        |                         |                                     |
| 39,963                     | Female 23.5% 27.3% 21.5%           |                        |                         |                                     |
| Female 23.5% 27.3%         | 17.8% 20.3%                        |                        |                         |                                     |
| 21.5% 17.8% 20.3%          | 18 - 24 0.0% 0.0% 0.0%             |                        |                         |                                     |

| Maintenance Measure       | Maintenance Measure        | Endorsed Measure 0736: | New Candidate           | New Candidate Standard      |
|---------------------------|----------------------------|------------------------|-------------------------|-----------------------------|
| 0357: Abdominal aortic    | 0359: Abdominal aortic     | Survival predictor for | Standard 1523: In-      | 1534: In-hospital mortality |
| aneurysm (AAA) repair     | artery (AAA) repair        | abdominal aortic       | hospital mortality      | following elective EVAR     |
| volume (IQI 4)            | mortality rate (IQI 11)    | aneurysm (AAA)         | following elective open | of small AAAs               |
|                           |                            |                        | repair of small AAAs    |                             |
| 18 - 24 0.0% 0.0% 0.0%    | 0.0% 0.0%                  |                        |                         |                             |
| 0.0% 0.0%                 | 25 - 29 0.1% 0.1% 0.0%     |                        |                         |                             |
| 25 - 29 0.1% 0.1% 0.0%    | 0.0% 0.0%                  |                        |                         |                             |
| 0.0% 0.0%                 | 30 - 34 0.0% 0.1% 0.0%     |                        |                         |                             |
| 30 - 34 0.0% 0.1% 0.0%    | 0.0% 0.0%                  |                        |                         |                             |
| 0.0% 0.0%                 | 35 - 39 0.0% 0.1% 0.1%     |                        |                         |                             |
| 35 - 39 0.0% 0.1% 0.1%    | 0.0% 0.1%                  |                        |                         |                             |
| 0.0% 0.1%                 | 40 - 44 0.1% 0.5% 0.0%     |                        |                         |                             |
| 40 - 44 0.1% 0.5% 0.0%    | 0.1% 0.1%                  |                        |                         |                             |
| 0.1% 0.1%                 | 45 - 49 0.8% 0.9% 0.8%     |                        |                         |                             |
| 45 - 49 0.8% 0.9% 0.8%    | 0.3% 0.5%                  |                        |                         |                             |
| 0.3% 0.5%                 | 50 - 54 1.9% 2.4% 1.8%     |                        |                         |                             |
| 50 - 54 1.9% 2.4% 1.8%    | 1.2% 1.5%                  |                        |                         |                             |
| 1.2% 1.5%                 | 55 - 59 4.7% 6.3% 5.8%     |                        |                         |                             |
| 55 - 59 4.7% 6.3% 5.8%    | 3.5% 4.3%                  |                        |                         |                             |
| 3.5% 4.3%                 | 60 - 64 11.0% 12.5% 9.0%   |                        |                         |                             |
| 60 - 64 11.0% 12.5% 9.0%  | 9.4% 10.2%                 |                        |                         |                             |
| 9.4% 10.2%                | 70 - 74 18.7% 21.4% 14.9%  |                        |                         |                             |
| 70 - 74 18.7% 21.4% 14.9% | 20.1% 20.2%                |                        |                         |                             |
| 20.1% 20.2%               | 75 - 79 19.7% 20.5% 16.4%  |                        |                         |                             |
| 75 - 79 19.7% 20.5% 16.4% | 22.2% 21.6%                |                        |                         |                             |
| 22.2% 21.6%               | 80 - 84 17.3% 11.5% 19.7%  |                        |                         |                             |
| 80 - 84 17.3% 11.5% 19.7% | 17.3% 16.1%                |                        |                         |                             |
| 17.3% 16.1%               | 85 - high 10.0% 4.3% 16.8% |                        |                         |                             |
| 85 - high 10.0% 4.3%      | 9.4% 8.5%                  |                        |                         |                             |
| 16.8% 9.4% 8.5%           | 169-1 0.0% 26.7% 0.1%      |                        |                         |                             |
| 169-1 0.0% 26.7% 0.1%     | 0.6% 6.3%                  |                        |                         |                             |
| 0.6% 6.3%                 | 169-2 0.0% 30.2% 0.0%      |                        |                         |                             |
| 169-2 0.0% 30.2% 0.0%     | 1.1% 7.3%                  |                        |                         |                             |
| 1.1% 7.3%                 | 169-3 0.1% 21.1% 0.0%      |                        |                         |                             |
| 169-3 0.1% 21.1% 0.0%     | 0.5% 5.0%                  |                        |                         |                             |
| 0.5% 5.0%                 | 169-4 88.4% 14.5% 6.2%     |                        |                         |                             |

| Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4) | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11) | <b>Endorsed Measure 0736:</b><br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA) | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open | <b>New Candidate Standard</b><br><b>1534</b> : In-hospital mortality<br>following elective EVAR<br>of small AAAs |
|--|---|---|--|--|
|  |   |   | repair of small AAAs   |  |
| 169-4 88.4% 14.5% 6.2%   | 0.4% 8.6%   |   |  |  |
| 0.4% 8.6%  | 173-2 0.0% 0.0% 0.0%  |   |  |  |
| 173-2 0.0% 0.0% 0.0%   | 35.1% 24.6%   |   |  |  |
| 35.1% 24.6%  | 173-3 0.0% 0.0% 0.1% 7.6%   |   |  |  |
| 173-3 0.0% 0.0% 0.1%   | 5.3%  |   |  |  |
| 7.6% 5.3%  | 173-4 0.0% 0.0% 84.4%   |   |  |  |
| 173-4 0.0% 0.0% 84.4%  | 2.3% 3.8%   |   |  |  |
| 2.3% 3.8%  | MDC 5 11.5% 7.5% 9.2%   |   |  |  |
| MDC 5 11.5% 7.5% 9.2%  | 2.1% 4.0%   |   |  |  |
| 2.1% 4.0%  | Transfer-in 14.5% 2.4%  |   |  |  |
| Transfer-in 14.5% 2.4%   | 18.5% 1.6% 2.9%   |   |  |  |
| 18.5% 1.6% 2.9%  | Source: State Inpatient   |   |  |  |
| Source: State Inpatient  | Databases (SID),  |   |  |  |
| Databases (SID),   | Healthcare Cost and   |   |  |  |
| Healthcare Cost and  | Utilization Project   |   |  |  |
| Utilization Project  | (HCUP). APR-DRG 169   |   |  |  |
| (HCUP). APR-DRG 169  | (MAJOR THORACIC &   |   |  |  |
| (MAJOR THORACIC &  | ABDOMINAL   |   |  |  |
| ABDOMINAL  | VASCULAR  |   |  |  |
| VASCULAR   | PROCEDURES); APR-   |   |  |  |
| PROCEDURES); APR-  | DRG 173 (OTHER  |   |  |  |
| DRG 173 (OTHER   | VASCULAR  |   |  |  |
| VASCULAR   | PROCEDURES)   |   |  |  |
| PROCEDURES)  |   |   |  |  |
|  | Table 2B. Model   |   |  |  |
| Table 2B. Model  | Covariates, 2008  |   |  |  |
| Covariates, 2008   | Open, Ruptured Open,  |   |  |  |
| Open, Ruptured Open,   | Un-ruptured   |   |  |  |
| Un-ruptured  | Endovascular, Ruptured  |   |  |  |
| Endovascular,  | Endovascular, Ruptured  |   |  |  |
| Ruptured Endovascular,   | Un-ruptured Original  |   |  |  |
| Ruptureu Enuovascular,   | On-ruptured Original  | 1   | L  |  |

| Maintenance Measure         | Maintenance Measure          | Endorsed Measure 0736: | New Candidate           | New Candidate Standard      |
|-----------------------------|------------------------------|------------------------|-------------------------|-----------------------------|
| 0357: Abdominal aortic      | 0359: Abdominal aortic       | Survival predictor for | Standard 1523: In-      | 1534: In-hospital mortality |
| aneurysm (AAA) repair       | artery (AAA) repair          | abdominal aortic       | hospital mortality      | following elective EVAR     |
| volume (IQI 4)              | mortality rate (IQI 11)      | aneurysm (AAA)         | following elective open | of small AAAs               |
|                             |                              |                        | repair of small AAAs    |                             |
| Un-ruptured Original        | (Composite)                  |                        |                         |                             |
| (Composite)                 | Odds Ratios                  |                        |                         |                             |
| Odds Ratios                 | Female 1.116 1.063 1.548*    |                        |                         |                             |
| Female 1.116 1.063 1.548*   | 1.386* 1.143*                |                        |                         |                             |
| 1.386* 1.143*               | 18 - 24                      |                        |                         |                             |
| 18 - 24                     | 25 - 29                      |                        |                         |                             |
| 25 - 29                     | 30 - 34                      |                        |                         |                             |
| 30 - 34                     | 35 - 39                      |                        |                         |                             |
| 35 - 39                     | 40 - 44                      |                        |                         |                             |
| 40 - 44                     | 45 - 49 0.538 0.634 0.387    |                        |                         |                             |
| 45 - 49 0.538 0.634 0.387   | 50 - 54 0.445 0.483 1.761    |                        |                         |                             |
| 50 - 54 0.445 0.483 1.761   | 0.637                        |                        |                         |                             |
| 0.637                       | 55 - 59 0.547* 0.713 0.526   |                        |                         |                             |
| 55 - 59 0.547* 0.713 0.526  | 1.068 0.644*                 |                        |                         |                             |
| 1.068 0.644*                | 60 - 64 0.910 0.814 1.048    |                        |                         |                             |
| 60 - 64 0.910 0.814 1.048   | 1.613 0.999                  |                        |                         |                             |
| 1.613 0.999                 | 70 - 74 1.721* 1.023 1.699   |                        |                         |                             |
| 70 - 74 1.721* 1.023 1.699  | 1.138 1.328*                 |                        |                         |                             |
| 1.138 1.328*                | 75 - 79 1.804* 1.410 1.800*  |                        |                         |                             |
| 75 - 79 1.804* 1.410 1.800* | 1.862* 1.569*                |                        |                         |                             |
| 1.862* 1.569*               | 80 - 84 2.941* 2.459* 2.346* |                        |                         |                             |
| 80 - 84 2.941* 2.459*       | 2.002* 2.499*                |                        |                         |                             |
| 2.346* 2.002* 2.499*        | 85 - high 4.225* 2.469*      |                        |                         |                             |
| 85 - high 4.225* 2.469*     | 2.052* 2.717* 3.006*         |                        |                         |                             |
| 2.052* 2.717* 3.006*        | 169-1 0.052* 41.786*         |                        |                         |                             |
| 169-1 0.052* 41.786*        | 13.066*                      |                        |                         |                             |
| 13.066*                     | 169-2 0.070* 15.660*         |                        |                         |                             |
| 169-2 0.070* 15.660*        | 13.998*                      |                        |                         |                             |
| 13.998*                     | 169-3 0.284* 71.019*         |                        |                         |                             |
| 169-3 0.284* 71.019*        | 55.144*                      |                        |                         |                             |
| 55.144*                     | 169-4 1.375* 2.372* 1.587    |                        |                         |                             |
| 169-4 1.375* 2.372* 1.587   | 173-2 1.576 1.470            |                        |                         |                             |

|            | Maintenance Measure   | Maintenance Measure   | Endorsed Measure 0736: | New Candidate   | New Candidate Standard  |
|------------|---|---|------------------------|---|---|
|            | 0357: Abdominal aortic  | 0359: Abdominal aortic  | Survival predictor for | Standard 1523: In-  | <b>1534</b> : In-hospital mortality   |
|            | aneurysm (AAA) repair   | artery (AAA) repair   | abdominal aortic       | hospital mortality  | following elective EVAR   |
|            | volume (IQI 4)  | mortality rate (IQI 11)   | aneurysm (AAA)         | following elective open<br>repair of small AAAs   | of small AAAs   |
|            | 173-2 1.576 1.470<br>173-3 32.328* 30.741*<br>173-4 0.789<br>MDC 5 1.000 1.000 1.000<br>1.000 1.000<br>Transfer-in 0.948 0.779<br>1.011 1.824* 1.251*<br>C-statistic 0.659 0.868<br>0.626 0.942 0.940<br>Source: State Inpatient<br>Databases (SID),<br>Healthcare Cost and | 173-3 32.328* 30.741*<br>173-4 0.789<br>MDC 5 1.000 1.000 1.000<br>1.000 1.000<br>Transfer-in 0.948 0.779<br>1.011 1.824* 1.251*<br>C-statistic 0.659 0.868 0.626<br>0.942 0.940<br>Source: State Inpatient<br>Databases (SID),<br>Healthcare Cost and<br>Utilization Project   |                        |   |   |
|            | Utilization Project<br>(HCUP); * - significant at<br>p<.05  | (HCUP); * - significant at<br>p<.05   |                        |   |   |
| Type Score | Count   | Rate/proportion   |                        | Rate/proportion   | Rate/proportion   |
| Algorithm  | The volume is the<br>number of discharges<br>with a diagnosis of, and a<br>procedure for AAA.<br>There are four volume<br>strata: open vs.<br>endovascular, and ruptured<br>vs. un-ruptured.  | There are four rates<br>calculated, one for each<br>stratum (open vs.<br>endovascular, ruptured vs.<br>un-ruptured). Each<br>stratum indicator is<br>expressed as a rate, and is<br>defined as outcome of<br>interest / population at<br>risk or numerator /<br>denominator. The AHRQ<br>Quality Indicators (AHRQ<br>QI) software performs<br>several steps to produce<br>the rates. 1) Discharge-<br>level data is used to |                        | Identify denominator,<br>exclude non-elective<br>repair of symptomatic or<br>ruptured patients and<br>men with AAA >6 cm,<br>and women with AAA<br>>5.5, find number of<br>deaths<br>Outcome = deaths/ #<br>cases | Identify denominator,<br>exclude non-elective<br>repair of symptomatic or<br>ruptured patients and<br>men with AAA >6 cm,<br>and women with AAA<br>>5.5, find number of<br>deaths<br>Outcome = deaths/ #<br>cases |

| Maintenance Measure    | Maintenance Measure          | Endorsed Measure 0736: | New Candidate           | New Candidate Standard      |
|------------------------|------------------------------|------------------------|-------------------------|-----------------------------|
| 0357: Abdominal aortic | 0359: Abdominal aortic       | Survival predictor for | Standard 1523: In-      | 1534: In-hospital mortality |
| aneurysm (AAA) repair  | artery (AAA) repair          | abdominal aortic       | hospital mortality      | following elective EVAR     |
| volume (IQI 4)         | mortality rate (IQI 11)      | aneurysm (AAA)         | following elective open | of small AAAs               |
|                        |                              |                        | repair of small AAAs    |                             |
|                        | identify inpatient records   |                        |                         |                             |
|                        | containing the outcome of    |                        |                         |                             |
|                        | interest and 2) the          |                        |                         |                             |
|                        | population at risk. For      |                        |                         |                             |
|                        | provider indicators, the     |                        |                         |                             |
|                        | population at risk is        |                        |                         |                             |
|                        | derived from hospital        |                        |                         |                             |
|                        | discharge records; 3)        |                        |                         |                             |
|                        | Calculate observed rates.    |                        |                         |                             |
|                        | Using output from steps 1    |                        |                         |                             |
|                        | and 2, rates are calculated  |                        |                         |                             |
|                        | for user-specified           |                        |                         |                             |
|                        | combinations of stratifiers. |                        |                         |                             |
|                        | 4) Calculate expected        |                        |                         |                             |
|                        | rates. Regression            |                        |                         |                             |
|                        | coefficients from a          |                        |                         |                             |
|                        | reference population         |                        |                         |                             |
|                        | database are applied to the  |                        |                         |                             |
|                        | discharge records and        |                        |                         |                             |
|                        | aggregated to the provider   |                        |                         |                             |
|                        | level. 5) Calculate risk-    |                        |                         |                             |
|                        | adjusted rate. Use the       |                        |                         |                             |
|                        | indirect standardization to  |                        |                         |                             |
|                        | account for case-mix. 6)     |                        |                         |                             |
|                        | Calculate smoothed rate.     |                        |                         |                             |
|                        | A multi-variate shrinkage    |                        |                         |                             |
|                        | factor is applied to the     |                        |                         |                             |
|                        | risk-adjusted rates. The     |                        |                         |                             |
|                        | shrinkage estimate reflects  |                        |                         |                             |
|                        | a reliability adjustment     |                        |                         |                             |
|                        | unique to each indicator     |                        |                         |                             |
|                        | and hospital, and takes      |                        |                         |                             |

| Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4) | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11)  | <b>Endorsed Measure 0736:</b><br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA) | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs | New Candidate Standard<br>1534: In-hospital mortality<br>following elective EVAR<br>of small AAAs |
|--|--|---|--|---|
|  | into account both the<br>signal (between provider<br>variance) and noise<br>(within provider variance)<br>for the indicator in each<br>stratum, but also the<br>covariance with the<br>indicators across stratum.<br>The smoothed rate is a<br>weighted average of the<br>hospital- and stratum-<br>specific risk-adjusted rate<br>and the volume- and<br>stratum-specific risk-<br>adjusted rate, where the<br>weight is the multi-variate<br>shrinkage factor; 7)<br>Calculate combined rate<br>across stratum. The<br>overall rate is a weighted<br>average of the stratum-<br>specific rates. The<br>"disease" weights are the<br>relative frequency of<br>ruptured and un-ruptured<br>cases in the reference<br>population. The<br>"procedure" weights are<br>the relative frequency of<br>open and endovascular<br>cases in the hospital. The<br>stratum weight is the |   |  |   |

|                                      | Maintenance Measure<br>0357: Abdominal aortic<br>aneurysm (AAA) repair<br>volume (IQI 4) | Maintenance Measure<br>0359: Abdominal aortic<br>artery (AAA) repair<br>mortality rate (IQI 11)<br>disease weight multiplied<br>by the procedure weight<br>and the sum of weights<br>across stratum is<br>normalized to 1.0.<br>Additional information on<br>calculation algorithms and<br>specifications can be found<br>at<br>http://qualityindicators.a<br>hrq.gov/Downloads/Reso<br>urces/Publications/2011/<br>QI%20Empirical%20Meth<br>ods%2005-03-11.pdf | Endorsed Measure 0736:<br>Survival predictor for<br>abdominal aortic<br>aneurysm (AAA) | New Candidate<br>Standard 1523: In-<br>hospital mortality<br>following elective open<br>repair of small AAAs | New Candidate Standard<br>1534: In-hospital mortality<br>following elective EVAR<br>of small AAAs |
|--------------------------------------|--|---|--|--|---|
| Data Source                          | Electronic administrative<br>data/claims   | Electronic administrative<br>data/claims  | Electronic administrative<br>data/claims   | Registry data  | Registry data   |
| Level of<br>Measurement<br>/Analysis | Facility/agency  | Facility/agency   | Facility/agency  | Clinicians: Individual,<br>group; Facility/agency;<br>Can be measured at all<br>levels                       | Clinicians: Individual,<br>group; Facility/agency;<br>Can be measured at all<br>levels            |
| Care Settings                        | Hospital   | Hospital  | Hospital   | Hospital   | Hospital  |